_MEMBER_att_D_no_prior_0 - 1.8-2.2,_MEMBER_att_D_no_prior_0 - 4.5-5.5,_MEMBER_att_D_no_prior_0 - 9.0-11.0,_LogP_att_D_no_prior_0 - 1.8-2.2,_LogP_att_D_no_prior_0 - 4.5-5.5,_LogP_att_D_no_prior_0 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-2.3,-3.6,-2.4,GO:0051250,negative regulation of lymphocyte activation,M111,3,0
1,1,1,-9.9,-2.2,-2.1,hsa04659,Th17 cell differentiation,M111,3,0
1,1,1,-2.3,-4.3,-2.7,GO:0050864,regulation of B cell activation,M111,3,0
1,1,1,-16,-8.5,-4.9,GO:0001775,cell activation,M111,3,0
1,1,1,-9,-2.8,-3.3,GO:0045637,regulation of myeloid cell differentiation,M111,3,0
1,1,1,-2.6,-3.1,-2.4,GO:0045089,positive regulation of innate immune response,M111,3,0
1,1,1,-6.3,-2.4,-4.1,GO:0045639,positive regulation of myeloid cell differentiation,M111,3,0
1,1,1,-17,-7.5,-4.4,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-3.3,-3.4,-2.1,GO:0002695,negative regulation of leukocyte activation,M111,3,0
1,1,1,-4.7,-4,-3.7,GO:0034101,erythrocyte homeostasis,M111,3,0
1,1,1,-14,-2.2,-2.9,GO:0001819,positive regulation of cytokine production,M111,3,0
1,1,1,-8.4,-5.1,-2.3,GO:0050865,regulation of cell activation,M111,3,0
1,1,1,-8.7,-2.8,-2.2,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M111,3,0
1,1,1,-3.4,-5.2,-3.3,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M111,3,0
1,1,1,-3.2,-2.9,-3,GO:0002262,myeloid cell homeostasis,M111,3,0
1,1,1,-5.7,-4.1,-5.5,GO:0002263,cell activation involved in immune response,M111,3,0
1,1,1,-5.9,-5,-2.1,GO:0002757,immune response-activating signaling pathway,M111,3,0
1,1,1,-2.2,-3.4,-2.1,GO:1903707,negative regulation of hemopoiesis,M111,3,0
1,1,1,-7.1,-10,-5,WP3945,TYROBP causal network in microglia,M111,3,0
1,1,1,-3.1,-2.4,-3.7,GO:0030100,regulation of endocytosis,M111,3,0
1,1,1,-6.5,-3.2,-3.2,GO:0045785,positive regulation of cell adhesion,M111,3,0
1,1,1,-11,-5.5,-3.9,GO:0030098,lymphocyte differentiation,M111,3,0
1,1,1,-3.9,-2.1,-5.8,GO:0002285,lymphocyte activation involved in immune response,M111,3,0
1,1,1,-5,-3.6,-3.2,GO:0042113,B cell activation,M111,3,0
1,1,1,-6.9,-2.9,-2.2,GO:0002696,positive regulation of leukocyte activation,M111,3,0
1,1,1,-4.9,-3.1,-2.6,WP5130,Th17 cell differentiation pathway,M111,3,0
1,1,1,-7.5,-4.1,-2.4,M183,PID IL6 7 PATHWAY,M111,3,0
1,1,1,-8.8,-5.8,-3.9,GO:0050778,positive regulation of immune response,M111,3,0
1,1,1,-6.1,-5.1,-2.1,GO:0051249,regulation of lymphocyte activation,M111,3,0
1,1,1,-5.7,-4.1,-5.5,GO:0002366,leukocyte activation involved in immune response,M111,3,0
1,1,1,-4.9,-2.5,-2.3,GO:0002702,positive regulation of production of molecular mediator of immune response,M111,3,0
1,1,1,-3,-2.7,-2.2,GO:0002833,positive regulation of response to biotic stimulus,M111,3,0
1,1,1,-3.2,-2.4,-4.4,hsa04664,Fc epsilon RI signaling pathway,M111,3,0
1,1,1,-4.6,-5.7,-2.6,WP2882,Nuclear receptors meta pathway,M111,3,0
1,1,1,-2.5,-3.3,-2,GO:0071216,cellular response to biotic stimulus,M111,3,0
1,1,1,-4.5,-2.4,-2.1,hsa05169,Epstein-Barr virus infection,M111,3,0
1,1,1,-16,-7.4,-4.9,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-6.4,-3.1,-2.1,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-4,-3.5,-3,GO:0030183,B cell differentiation,M111,3,0
1,1,1,-6.8,-2.9,-2.1,GO:1903708,positive regulation of hemopoiesis,M111,3,0
1,1,1,-13,-7,-4.2,GO:1903131,mononuclear cell differentiation,M111,3,0
1,1,1,-2,-3.5,-2.1,GO:1902106,negative regulation of leukocyte differentiation,M111,3,0
1,1,1,-3.6,-2.8,-2.4,GO:0060627,regulation of vesicle-mediated transport,M111,3,0
1,1,1,-2.7,-4.1,-3.7,GO:0050764,regulation of phagocytosis,M111,3,0
1,1,1,-22,-11,-8.2,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-2.5,-2.1,-2.8,GO:0050871,positive regulation of B cell activation,M111,3,0
1,1,1,-9.4,-5.3,-2.7,GO:0010720,positive regulation of cell development,M111,3,0
1,1,1,-2.2,-2.7,-3.2,GO:0032655,regulation of interleukin-12 production,M111,3,0
1,1,1,-2.8,-3.7,-3.1,GO:0048872,homeostasis of number of cells,M111,3,0
1,1,1,-2.1,-2.7,-2.3,GO:0071219,cellular response to molecule of bacterial origin,M111,3,0
1,1,1,-15,-7.1,-4,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-4.9,-2.9,-2.5,GO:0022409,positive regulation of cell-cell adhesion,M111,3,0
1,1,1,-5.6,-4.3,-4.6,GO:0002252,immune effector process,M111,3,0
1,1,1,-6.6,-4.1,-2.1,GO:0002819,regulation of adaptive immune response,M111,3,0
1,1,1,-17,-5.2,-2.2,R-HSA-1280215,Cytokine Signaling in Immune system,M111,3,0
1,1,1,-6.8,-2.9,-2.1,GO:1902107,positive regulation of leukocyte differentiation,M111,3,0
1,1,1,-5.8,-3.6,-2.7,GO:0002761,regulation of myeloid leukocyte differentiation,M111,3,0
1,1,1,-4,-3.2,-2,hsa04662,B cell receptor signaling pathway,M111,3,0
1,1,1,-2.9,-3.2,-2.9,GO:0046456,icosanoid biosynthetic process,M111,3,0
1,1,1,-5.7,-6.8,-2.6,GO:0002683,negative regulation of immune system process,M111,3,0
1,1,1,-6.6,-4.4,-2.5,GO:0002764,immune response-regulating signaling pathway,M111,3,0
1,1,1,-6.5,-3.6,-2.9,GO:0032103,positive regulation of response to external stimulus,M111,3,0
1,1,1,-4.3,-2,-2.2,GO:0045646,regulation of erythrocyte differentiation,M111,3,0
1,1,1,-4.8,-4.3,-3.9,GO:0030218,erythrocyte differentiation,M111,3,0
1,1,1,-14,-7.2,-4.3,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-5.3,-3.7,-4,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,1,-8,-5.8,-2.7,GO:0002694,regulation of leukocyte activation,M111,3,0
1,1,1,-7.9,-2.6,-2.1,GO:0050867,positive regulation of cell activation,M111,3,0
1,1,1,-3.8,-3.1,-2.2,GO:0050777,negative regulation of immune response,M111,3,0
1,1,0,-2.7,-2.6,0,WP2880,Glucocorticoid receptor pathway,M110,2,0
1,1,0,-5.7,-2.7,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-4.1,-3.8,0,M255,PID HIF1 TFPATHWAY,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0033077,T cell differentiation in thymus,M110,2,0
1,1,0,-2.8,-2.9,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M110,2,0
1,0,1,-2.3,0,-2.5,GO:0008593,regulation of Notch signaling pathway,M101,2,0
1,1,0,-2.8,-3.7,0,WP4844,Influence of laminopathies on Wnt signaling,M110,2,0
1,1,0,-3.9,-2,0,GO:0045669,positive regulation of osteoblast differentiation,M110,2,0
1,0,1,-4.2,0,-2.1,GO:0002763,positive regulation of myeloid leukocyte differentiation,M101,2,0
1,1,0,-3.3,-2,0,WP4262,Breast cancer pathway,M110,2,0
1,1,0,-8.1,-4.8,0,GO:0045596,negative regulation of cell differentiation,M110,2,0
1,1,0,-3.9,-3.7,0,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-6.1,-2.8,0,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M110,2,0
1,1,0,-3,-2.1,0,GO:0021537,telencephalon development,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0045586,regulation of gamma-delta T cell differentiation,M110,2,0
1,1,0,-4.1,-2.4,0,GO:0120162,positive regulation of cold-induced thermogenesis,M110,2,0
1,1,0,-2.2,-3.3,0,hsa05216,Thyroid cancer,M110,2,0
1,1,0,-2.4,-2.5,0,GO:2000107,negative regulation of leukocyte apoptotic process,M110,2,0
0,1,1,0,-2.4,-3.1,GO:0002688,regulation of leukocyte chemotaxis,M011,2,0
1,1,0,-2.8,-2.2,0,GO:0045622,regulation of T-helper cell differentiation,M110,2,0
1,0,1,-2.1,0,-3.5,GO:0071425,hematopoietic stem cell proliferation,M101,2,0
1,1,0,-3.3,-2.4,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M110,2,0
1,1,0,-8.2,-4.6,0,GO:0002697,regulation of immune effector process,M110,2,0
1,1,0,-2.2,-2.2,0,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-4.4,-3.7,0,GO:0046634,regulation of alpha-beta T cell activation,M110,2,0
1,1,0,-3.8,-4.3,0,M10,PID BCR 5PATHWAY,M110,2,0
1,1,0,-5.5,-2.9,0,hsa04658,Th1 and Th2 cell differentiation,M110,2,0
1,1,0,-4.1,-2.2,0,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M110,2,0
1,1,0,-4.3,-2.7,0,GO:0042472,inner ear morphogenesis,M110,2,0
1,0,1,-3.5,0,-2.7,R-HSA-2559583,Cellular Senescence,M101,2,0
1,1,0,-2.6,-2.6,0,GO:0002758,innate immune response-activating signaling pathway,M110,2,0
1,0,1,-4,0,-3.3,GO:0032675,regulation of interleukin-6 production,M101,2,0
1,1,0,-2.6,-3.8,0,GO:0045471,response to ethanol,M110,2,0
1,1,0,-10,-4.9,0,GO:1903706,regulation of hemopoiesis,M110,2,0
1,1,0,-2.3,-2.3,0,GO:0045666,positive regulation of neuron differentiation,M110,2,0
1,1,0,-5,-4.4,0,GO:0002429,immune response-activating cell surface receptor signaling pathway,M110,2,0
1,1,0,-4.6,-4.7,0,M60,PID NFAT TFPATHWAY,M110,2,0
1,1,0,-2.5,-2.4,0,GO:0022030,telencephalon glial cell migration,M110,2,0
1,1,0,-2.2,-2.2,0,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M110,2,0
1,1,0,-2.7,-2,0,hsa05418,Fluid shear stress and atherosclerosis,M110,2,0
1,1,0,-2,-3.9,0,CORUM:2695,ETS2-FOS-JUN complex,M110,2,0
1,1,0,-3.1,-2.6,0,M63,PID AVB3 OPN PATHWAY,M110,2,0
1,1,0,-5.8,-3.3,0,GO:0001818,negative regulation of cytokine production,M110,2,0
1,1,0,-11,-2.2,0,hsa05200,Pathways in cancer,M110,2,0
1,1,0,-3.2,-2.2,0,hsa05135,Yersinia infection,M110,2,0
1,1,0,-4.2,-2.6,0,GO:0030278,regulation of ossification,M110,2,0
1,1,0,-2.5,-2.4,0,GO:0021801,cerebral cortex radial glia-guided migration,M110,2,0
1,1,0,-7.4,-2.5,0,R-HSA-9031628,NGF-stimulated transcription,M110,2,0
1,1,0,-5.5,-3.4,0,hsa05417,Lipid and atherosclerosis,M110,2,0
1,1,0,-3.3,-2.1,0,WP5090,Complement system in neuronal development and plasticity,M110,2,0
1,1,0,-6.9,-3,0,GO:2000630,positive regulation of miRNA metabolic process,M110,2,0
1,1,0,-5.7,-2.1,0,GO:0051251,positive regulation of lymphocyte activation,M110,2,0
1,1,0,-9.4,-2.8,0,GO:0070848,response to growth factor,M110,2,0
1,1,0,-3.5,-2.1,0,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M110,2,0
1,1,0,-3.4,-2.8,0,WP2023,Cell differentiation expanded index,M110,2,0
1,1,0,-5.2,-4.2,0,M235,PID TCR CALCIUM PATHWAY,M110,2,0
1,1,0,-3.8,-2.4,0,GO:0045807,positive regulation of endocytosis,M110,2,0
1,1,0,-3.9,-2.9,0,GO:0009611,response to wounding,M110,2,0
1,0,1,-2.3,0,-2.3,GO:0032479,regulation of type I interferon production,M101,2,0
1,0,1,-3.1,0,-2.6,GO:2000146,negative regulation of cell motility,M101,2,0
1,0,1,-4.1,0,-2.1,GO:1901652,response to peptide,M101,2,0
1,1,0,-4,-2.3,0,GO:0042471,ear morphogenesis,M110,2,0
1,1,0,-5.2,-3.8,0,WP2064,Neural crest differentiation,M110,2,0
1,1,0,-7.3,-7.8,0,WP23,B cell receptor signaling pathway,M110,2,0
1,1,0,-3.6,-3.1,0,GO:0002237,response to molecule of bacterial origin,M110,2,0
1,1,0,-2.2,-2.6,0,GO:0002218,activation of innate immune response,M110,2,0
1,1,0,-3.7,-3.1,0,GO:0060395,SMAD protein signal transduction,M110,2,0
0,1,1,0,-2.1,-2.8,GO:0002313,mature B cell differentiation involved in immune response,M011,2,0
1,1,0,-2.3,-2.4,0,hsa04932,Non-alcoholic fatty liver disease,M110,2,0
1,1,0,-5.2,-3,0,GO:0031349,positive regulation of defense response,M110,2,0
1,1,0,-2.7,-2.2,0,GO:0016064,immunoglobulin mediated immune response,M110,2,0
1,1,0,-4.1,-2.5,0,GO:0048839,inner ear development,M110,2,0
1,1,0,-3.4,-2.3,0,GO:0006909,phagocytosis,M110,2,0
0,1,1,0,-2.6,-2.2,GO:0120031,plasma membrane bounded cell projection assembly,M011,2,0
1,0,1,-3.1,0,-2.7,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M101,2,0
1,1,0,-5.9,-3.3,0,GO:0022407,regulation of cell-cell adhesion,M110,2,0
1,1,0,-3.2,-2.9,0,M195,PID CMYB PATHWAY,M110,2,0
1,0,1,-3.1,0,-2.7,GO:0045648,positive regulation of erythrocyte differentiation,M101,2,0
1,1,0,-2.4,-2,0,GO:0046639,negative regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-2.9,-2.4,0,GO:0009615,response to virus,M110,2,0
0,1,1,0,-2.7,-2.2,GO:0045088,regulation of innate immune response,M011,2,0
1,1,0,-3.6,-2.5,0,M17200,SA B CELL RECEPTOR COMPLEXES,M110,2,0
1,1,0,-4,-2.7,0,hsa04660,T cell receptor signaling pathway,M110,2,0
1,1,0,-4.8,-2.1,0,R-HSA-5621481,C-type lectin receptors (CLRs),M110,2,0
1,1,0,-5,-2.6,0,WP2355,Corticotropin releasing hormone signaling pathway,M110,2,0
1,1,0,-3.6,-2.5,0,GO:0046638,positive regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-5.1,-2.2,0,GO:0045598,regulation of fat cell differentiation,M110,2,0
1,1,0,-2.6,-2.2,0,GO:0030832,regulation of actin filament length,M110,2,0
1,1,0,-3.4,-2.9,0,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-6.7,-2.5,0,R-HSA-166520,Signaling by NTRKs,M110,2,0
0,1,1,0,-2.4,-3.6,GO:0002312,B cell activation involved in immune response,M011,2,0
1,0,1,-3.2,0,-3,GO:2001185,"regulation of CD8-positive, alpha-beta T cell activation",M101,2,0
1,1,0,-4.6,-2.5,0,WP4211,Transcriptional cascade regulating adipogenesis,M110,2,0
1,1,0,-3.3,-2.4,0,GO:0045588,positive regulation of gamma-delta T cell differentiation,M110,2,0
1,1,0,-2.4,-4,0,WP3937,Microglia pathogen phagocytosis pathway,M110,2,0
1,1,0,-11,-2.7,0,GO:2000628,regulation of miRNA metabolic process,M110,2,0
1,1,0,-5.2,-3.9,0,R-HSA-9012999,RHO GTPase cycle,M110,2,0
1,1,0,-6.5,-2.2,0,GO:2000147,positive regulation of cell motility,M110,2,0
0,1,1,0,-2.9,-2.8,GO:0030031,cell projection assembly,M011,2,0
1,1,0,-3.3,-2.4,0,GO:0019370,leukotriene biosynthetic process,M110,2,0
1,1,0,-2,-3.9,0,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M110,2,0
1,1,0,-4.9,-3.4,0,GO:0002718,regulation of cytokine production involved in immune response,M110,2,0
1,0,1,-5.6,0,-2.4,WP5198,Inflammatory bowel disease signaling,M101,2,0
1,1,0,-3.3,-2.4,0,GO:0098883,synapse pruning,M110,2,0
1,1,0,-9.7,-3.1,0,WP236,Adipogenesis,M110,2,0
1,1,0,-5.9,-2.6,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M110,2,0
1,1,0,-3.3,-3,0,GO:1902075,cellular response to salt,M110,2,0
1,1,0,-6.3,-3,0,GO:1901699,cellular response to nitrogen compound,M110,2,0
1,1,0,-4.3,-2.1,0,GO:0043583,ear development,M110,2,0
1,1,0,-3.7,-2,0,hsa05131,Shigellosis,M110,2,0
1,1,0,-3.1,-2.7,0,GO:0060759,regulation of response to cytokine stimulus,M110,2,0
1,1,0,-4.8,-3.5,0,WP3527,Pre implantation embryo,M110,2,0
0,1,1,0,-2.1,-2.3,GO:0033559,unsaturated fatty acid metabolic process,M011,2,0
1,1,0,-3.7,-2.8,0,R-HSA-9013149,RAC1 GTPase cycle,M110,2,0
1,1,0,-6.8,-3.4,0,GO:1902895,positive regulation of miRNA transcription,M110,2,0
1,1,0,-2.5,-2.1,0,GO:0019724,B cell mediated immunity,M110,2,0
1,1,0,-5.5,-3,0,GO:0002703,regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-3.6,-2.4,0,WP5322,CKAP4 signaling pathway map,M110,2,0
1,1,0,-2.6,-2.6,0,GO:0002275,myeloid cell activation involved in immune response,M110,2,0
1,1,0,-2.8,-3.4,0,GO:0045064,T-helper 2 cell differentiation,M110,2,0
1,1,0,-3,-6.6,0,M7,PID FCER1 PATHWAY,M110,2,0
1,1,0,-2.2,-2.5,0,GO:0031076,embryonic camera-type eye development,M110,2,0
0,1,1,0,-2.2,-2.2,GO:0051046,regulation of secretion,M011,2,0
1,1,0,-3.9,-3.2,0,GO:0050866,negative regulation of cell activation,M110,2,0
1,1,0,-2.6,-2.8,0,GO:0009620,response to fungus,M110,2,0
1,1,0,-3.7,-2.2,0,GO:2000177,regulation of neural precursor cell proliferation,M110,2,0
1,1,0,-3.6,-2.2,0,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M110,2,0
0,1,1,0,-2,-2.7,GO:0002335,mature B cell differentiation,M011,2,0
1,1,0,-8.4,-2.9,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M110,2,0
1,0,1,-4.6,0,-3.1,WP4585,Cancer immunotherapy by PD 1 blockade,M101,2,0
1,0,1,-5.4,0,-2.3,WP395,IL 4 signaling pathway,M101,2,0
1,1,0,-2,-2.4,0,GO:1990868,response to chemokine,M110,2,0
1,1,0,-3.2,-2.9,0,GO:1903844,regulation of cellular response to transforming growth factor beta stimulus,M110,2,0
1,1,0,-3.7,-2.3,0,GO:0048663,neuron fate commitment,M110,2,0
1,1,0,-13,-7.3,0,GO:0071345,cellular response to cytokine stimulus,M110,2,0
1,1,0,-5.2,-2,0,GO:0045621,positive regulation of lymphocyte differentiation,M110,2,0
1,0,1,-2.7,0,-2.7,GO:0002690,positive regulation of leukocyte chemotaxis,M101,2,0
1,1,0,-3,-3.8,0,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M110,2,0
1,0,1,-2.8,0,-2.7,GO:0010935,regulation of macrophage cytokine production,M101,2,0
1,1,0,-3,-2.8,0,GO:0050766,positive regulation of phagocytosis,M110,2,0
1,1,0,-7.2,-6.1,0,hsa05202,Transcriptional misregulation in cancer,M110,2,0
1,1,0,-5.1,-3.1,0,WP399,Wnt signaling pathway and pluripotency,M110,2,0
1,1,0,-3.9,-2.1,0,WP710,DNA damage response only ATM dependent,M110,2,0
1,1,0,-2.5,-3.8,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M110,2,0
1,1,0,-2.5,-3.4,0,GO:0014015,positive regulation of gliogenesis,M110,2,0
1,1,0,-3.4,-3.4,0,GO:0050851,antigen receptor-mediated signaling pathway,M110,2,0
1,1,0,-2.5,-3.3,0,GO:0048596,embryonic camera-type eye morphogenesis,M110,2,0
1,1,0,-2,-2.4,0,GO:0045185,maintenance of protein location,M110,2,0
1,1,0,-3.4,-2.1,0,GO:0010464,regulation of mesenchymal cell proliferation,M110,2,0
1,1,0,-4,-2.6,0,GO:1900016,negative regulation of cytokine production involved in inflammatory response,M110,2,0
1,1,0,-4.9,-2.2,0,GO:0030101,natural killer cell activation,M110,2,0
1,1,0,-4.1,-2.4,0,WP5102,Familial partial lipodystrophy,M110,2,0
1,1,0,-6.7,-2.7,0,WP4816,TGF beta receptor signaling in skeletal dysplasias,M110,2,0
1,1,0,-3.6,-2.3,0,R-HSA-194315,Signaling by Rho GTPases,M110,2,0
1,1,0,-5.6,-2.4,0,WP3594,Circadian rhythm genes,M110,2,0
1,0,1,-4.1,0,-2.2,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M101,2,0
1,1,0,-6.2,-2.5,0,GO:0051090,regulation of DNA-binding transcription factor activity,M110,2,0
1,0,1,-13,0,-2.5,GO:0001501,skeletal system development,M101,2,0
0,1,1,0,-3,-2.2,GO:0019722,calcium-mediated signaling,M011,2,0
1,1,0,-4.3,-2,0,M151,PID AR TF PATHWAY,M110,2,0
1,0,1,-4.3,0,-2.3,GO:0032760,positive regulation of tumor necrosis factor production,M101,2,0
1,1,0,-4,-2.2,0,GO:0006897,endocytosis,M110,2,0
1,0,1,-2.8,0,-2.7,GO:0030336,negative regulation of cell migration,M101,2,0
1,1,0,-6.7,-3.2,0,GO:0002573,myeloid leukocyte differentiation,M110,2,0
1,1,0,-3.2,-3.6,0,GO:0002443,leukocyte mediated immunity,M110,2,0
1,1,0,-6,-2.5,0,GO:0051345,positive regulation of hydrolase activity,M110,2,0
1,1,0,-2.8,-2.3,0,GO:0008064,regulation of actin polymerization or depolymerization,M110,2,0
1,1,0,-2.1,-4.3,0,GO:0050853,B cell receptor signaling pathway,M110,2,0
1,1,0,-3.9,-2.2,0,GO:0032677,regulation of interleukin-8 production,M110,2,0
1,1,0,-4.5,-3.2,0,R-HSA-8878159,Transcriptional regulation by RUNX3,M110,2,0
1,0,1,-2.9,0,-2.3,GO:0040013,negative regulation of locomotion,M101,2,0
1,1,0,-3.3,-5.4,0,GO:0050728,negative regulation of inflammatory response,M110,2,0
1,1,0,-6.9,-5.1,0,GO:0050727,regulation of inflammatory response,M110,2,0
1,1,0,-5,-2.1,0,GO:0051336,regulation of hydrolase activity,M110,2,0
1,1,0,-3.5,-4.3,0,GO:0046631,alpha-beta T cell activation,M110,2,0
1,1,0,-4.1,-2,0,GO:0043087,regulation of GTPase activity,M110,2,0
1,1,0,-4.9,-2.3,0,GO:0046651,lymphocyte proliferation,M110,2,0
1,1,0,-8.3,-3.4,0,GO:0006954,inflammatory response,M110,2,0
1,0,1,-3.3,0,-2.6,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M101,2,0
1,1,0,-3,-3.4,0,WP286,IL 3 signaling pathway,M110,2,0
1,1,0,-5,-2.4,0,GO:0045582,positive regulation of T cell differentiation,M110,2,0
1,1,0,-2.3,-2.6,0,GO:0060216,definitive hemopoiesis,M110,2,0
1,1,0,-7.3,-3.5,0,GO:0050767,regulation of neurogenesis,M110,2,0
1,1,0,-4.3,-2.5,0,GO:0044092,negative regulation of molecular function,M110,2,0
1,1,0,-8.4,-2.3,0,GO:0048562,embryonic organ morphogenesis,M110,2,0
1,1,0,-11,-2.8,0,GO:0140747,regulation of ncRNA transcription,M110,2,0
1,1,0,-2,-3.2,0,GO:0045577,regulation of B cell differentiation,M110,2,0
1,1,0,-4.9,-2.1,0,WP4659,Gastrin signaling pathway,M110,2,0
1,1,0,-2.3,-2.9,0,hsa05210,Colorectal cancer,M110,2,0
0,1,1,0,-3.6,-2.2,GO:0045058,T cell selection,M011,2,0
1,1,0,-2.2,-3.7,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M110,2,0
1,1,0,-2,-5.1,0,R-HSA-9658195,Leishmania infection,M110,2,0
1,1,0,-8.3,-6.6,0,M167,PID AP1 PATHWAY,M110,2,0
1,1,0,-3.6,-3.7,0,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M110,2,0
1,1,0,-5.8,-2.3,0,hsa04062,Chemokine signaling pathway,M110,2,0
1,1,0,-3.6,-2.5,0,M22,PID GMCSF PATHWAY,M110,2,0
1,1,0,-2.9,-4.2,0,GO:0042092,type 2 immune response,M110,2,0
1,1,0,-4.7,-2.4,0,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M110,2,0
0,1,1,0,-2.2,-3.8,GO:0071715,icosanoid transport,M011,2,0
1,1,0,-2.6,-2.9,0,GO:0031641,regulation of myelination,M110,2,0
1,1,0,-6.8,-7.6,0,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M110,2,0
1,1,0,-5.8,-4.3,0,GO:0002253,activation of immune response,M110,2,0
1,1,0,-3.9,-2.9,0,GO:1900015,regulation of cytokine production involved in inflammatory response,M110,2,0
1,1,0,-7,-2.1,0,WP560,TGF beta receptor signaling,M110,2,0
1,0,1,-2.6,0,-2.8,GO:0031342,negative regulation of cell killing,M101,2,0
1,1,0,-4.2,-3.2,0,WP366,TGF beta signaling pathway,M110,2,0
1,0,1,-7.4,0,-3.7,WP4666,Hepatitis B infection,M101,2,0
1,1,0,-4.2,-3.2,0,GO:0010721,negative regulation of cell development,M110,2,0
1,0,1,-8,0,-4.4,hsa05161,Hepatitis B,M101,2,0
1,1,0,-4,-2.5,0,WP69,T cell receptor signaling pathway,M110,2,0
1,1,0,-5,-3.7,0,GO:0045444,fat cell differentiation,M110,2,0
1,1,0,-4.4,-3.3,0,GO:0045580,regulation of T cell differentiation,M110,2,0
1,1,0,-5.7,-2.2,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M110,2,0
1,1,0,-4.5,-2.3,0,GO:0070661,leukocyte proliferation,M110,2,0
0,1,1,0,-2.9,-2.4,GO:0071222,cellular response to lipopolysaccharide,M011,2,0
1,0,1,-9.9,0,-2.4,hsa05166,Human T-cell leukemia virus 1 infection,M101,2,0
1,1,0,-3.7,-3.1,0,M124,PID CXCR4 PATHWAY,M110,2,0
1,1,0,-4.6,-2.9,0,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M110,2,0
1,0,1,-4.1,0,-3.5,GO:0002286,T cell activation involved in immune response,M101,2,0
1,1,0,-4.1,-2.6,0,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M110,2,0
1,1,0,-6.6,-3.6,0,GO:0071559,response to transforming growth factor beta,M110,2,0
1,1,0,-2.4,-2.2,0,GO:0002449,lymphocyte mediated immunity,M110,2,0
1,1,0,-2.1,-3.1,0,hsa05132,Salmonella infection,M110,2,0
1,1,0,-6.6,-4,0,GO:0051960,regulation of nervous system development,M110,2,0
1,1,0,-2.2,-2.6,0,GO:0032944,regulation of mononuclear cell proliferation,M110,2,0
1,1,0,-5.5,-2.2,0,GO:0050870,positive regulation of T cell activation,M110,2,0
1,1,0,-3.2,-2.9,0,M223,PID BETA CATENIN NUC PATHWAY,M110,2,0
1,0,1,-5.5,0,-3,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M101,2,0
1,1,0,-8.3,-2.5,0,WP4149,White fat cell differentiation,M110,2,0
1,1,0,-3.3,-2.4,0,GO:0043376,"regulation of CD8-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-4.6,-2.1,0,WP3995,Prion disease pathway,M110,2,0
1,1,0,-4.9,-3.3,0,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M110,2,0
1,1,0,-2.8,-3.4,0,WP167,Eicosanoid synthesis,M110,2,0
1,1,0,-11,-3.6,0,GO:0019221,cytokine-mediated signaling pathway,M110,2,0
1,0,1,-2.1,0,-2.1,GO:0002820,negative regulation of adaptive immune response,M101,2,0
1,1,0,-2.4,-2.6,0,GO:0048048,embryonic eye morphogenesis,M110,2,0
1,1,0,-7.9,-6,0,GO:1902105,regulation of leukocyte differentiation,M110,2,0
1,0,1,-3.1,0,-2,GO:0002685,regulation of leukocyte migration,M101,2,0
1,1,0,-2,-2.4,0,GO:1990869,cellular response to chemokine,M110,2,0
1,0,1,-2.9,0,-2.9,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M101,2,0
1,1,0,-2.7,-3.6,0,WP428,Wnt signaling,M110,2,0
1,1,0,-4.9,-2.2,0,GO:0051056,regulation of small GTPase mediated signal transduction,M110,2,0
1,1,0,-4.1,-3.3,0,GO:0046635,positive regulation of alpha-beta T cell activation,M110,2,0
1,1,0,-6.1,-2.7,0,GO:0071417,cellular response to organonitrogen compound,M110,2,0
1,0,1,-5.8,0,-3.1,GO:0032680,regulation of tumor necrosis factor production,M101,2,0
1,1,0,-2.5,-2.8,0,GO:2000377,regulation of reactive oxygen species metabolic process,M110,2,0
1,1,0,-14,-6.4,0,R-HSA-449147,Signaling by Interleukins,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0150146,cell junction disassembly,M110,2,0
1,1,0,-3.6,-2,0,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M110,2,0
1,1,0,-5.5,-2.4,0,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M110,2,0
1,0,1,-2,0,-3.1,GO:0006691,leukotriene metabolic process,M101,2,0
1,1,0,-5,-2.5,0,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M110,2,0
1,1,0,-4,-2.6,0,R-HSA-2871796,FCERI mediated MAPK activation,M110,2,0
1,1,0,-6.5,-3.7,0,GO:1903037,regulation of leukocyte cell-cell adhesion,M110,2,0
1,0,1,-2.6,0,-2.1,GO:0060760,positive regulation of response to cytokine stimulus,M101,2,0
1,1,0,-3.3,-3.3,0,GO:0032496,response to lipopolysaccharide,M110,2,0
1,1,0,-12,-2.7,0,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M110,2,0
1,0,1,-3,0,-2.4,R-HSA-1912422,Pre-NOTCH Expression and Processing,M101,2,0
1,1,0,-5.6,-3.8,0,GO:0045087,innate immune response,M110,2,0
1,1,0,-2,-2.5,0,GO:0046641,positive regulation of alpha-beta T cell proliferation,M110,2,0
1,1,0,-2.3,-2.6,0,R-HSA-912631,Regulation of signaling by CBL,M110,2,0
1,1,0,-6.1,-3.2,0,hsa04928,"Parathyroid hormone synthesis, secretion and action",M110,2,0
1,1,0,-2.5,-3.3,0,M290,PID IL12 STAT4 PATHWAY,M110,2,0
1,1,0,-7,-2.1,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M110,2,0
1,1,0,-9.5,-2.5,0,hsa04380,Osteoclast differentiation,M110,2,0
1,1,0,-4.5,-5.8,0,GO:0009617,response to bacterium,M110,2,0
1,1,0,-3.9,-2.2,0,GO:0046645,positive regulation of gamma-delta T cell activation,M110,2,0
1,1,0,-9.2,-2.1,0,GO:0008283,cell population proliferation,M110,2,0
1,1,0,-4,-2.1,0,GO:0043547,positive regulation of GTPase activity,M110,2,0
1,1,0,-6,-2.9,0,GO:0002250,adaptive immune response,M110,2,0
1,1,0,-4.8,-2.4,0,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-2,-3,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M110,2,0
1,1,0,-2.1,-3.4,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M110,2,0
1,1,0,-5.1,-2.5,0,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M110,2,0
1,1,0,-9.2,-2.7,0,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M110,2,0
1,1,0,-5.6,-3.9,0,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M110,2,0
1,1,0,-7.5,-3.7,0,GO:0030217,T cell differentiation,M110,2,0
1,1,0,-4.9,-2.3,0,GO:0032943,mononuclear cell proliferation,M110,2,0
1,0,1,-6.4,0,-2.2,hsa05163,Human cytomegalovirus infection,M101,2,0
1,0,1,-3.6,0,-3.3,GO:0061515,myeloid cell development,M101,2,0
1,1,0,-5.4,-2.5,0,WP3929,Chemokine signaling pathway,M110,2,0
1,1,0,-7.3,-2.1,0,GO:0007167,enzyme-linked receptor protein signaling pathway,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0050832,defense response to fungus,M110,2,0
1,1,0,-6,-2.1,0,GO:0040017,positive regulation of locomotion,M110,2,0
1,1,0,-3.1,-2.3,0,GO:0032649,regulation of type II interferon production,M110,2,0
1,1,0,-5.8,-2.7,0,GO:0002274,myeloid leukocyte activation,M110,2,0
1,1,0,-4,-3.1,0,GO:0045664,regulation of neuron differentiation,M110,2,0
1,1,0,-5.1,-3.8,0,GO:0002700,regulation of production of molecular mediator of immune response,M110,2,0
1,0,1,-2.5,0,-2.7,hsa05220,Chronic myeloid leukemia,M101,2,0
1,1,0,-2.3,-2.6,0,WP5122,Prostaglandin and leukotriene metabolism in senescence,M110,2,0
1,1,0,-3.1,-2.3,0,GO:0051962,positive regulation of nervous system development,M110,2,0
1,0,1,-3,0,-2.2,GO:0032757,positive regulation of interleukin-8 production,M101,2,0
1,0,1,-3.4,0,-2,GO:0042116,macrophage activation,M101,2,0
1,1,0,-3,-2,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M110,2,0
1,1,0,-4.3,-2.5,0,GO:0097305,response to alcohol,M110,2,0
1,1,0,-3.1,-2.1,0,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-6.2,-2.1,0,GO:0030335,positive regulation of cell migration,M110,2,0
1,1,0,-11,-2.9,0,GO:1902893,regulation of miRNA transcription,M110,2,0
1,1,0,-4.9,-3.6,0,GO:0045619,regulation of lymphocyte differentiation,M110,2,0
1,1,0,-4.4,-2.8,0,GO:0050769,positive regulation of neurogenesis,M110,2,0
1,1,0,-2.2,-2.4,0,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M110,2,0
1,1,0,-5.4,-3.7,0,GO:0050863,regulation of T cell activation,M110,2,0
1,1,0,-3.6,-2.1,0,GO:0071356,cellular response to tumor necrosis factor,M110,2,0
1,1,0,-3.1,-2.5,0,GO:0014013,regulation of gliogenesis,M110,2,0
1,1,0,-3.9,-4.3,0,GO:0031348,negative regulation of defense response,M110,2,0
1,1,0,-4.9,-6.9,0,GO:0140467,integrated stress response signaling,M110,2,0
1,1,0,-3.4,-2,0,GO:0032729,positive regulation of type II interferon production,M110,2,0
1,0,1,-2.8,0,-2.4,GO:0043122,regulation of canonical NF-kappaB signal transduction,M101,2,0
1,0,1,-3.4,0,-2.2,WP3646,Hepatitis C and hepatocellular carcinoma,M101,2,0
1,1,0,-2,-3.9,0,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M110,2,0
1,1,0,-3.1,-2.9,0,GO:0001959,regulation of cytokine-mediated signaling pathway,M110,2,0
1,1,0,-12,-5,0,GO:0042110,T cell activation,M110,2,0
1,1,0,-3.6,-5.1,0,M186,PID PDGFRB PATHWAY,M110,2,0
1,1,0,-9.4,-4.5,0,GO:0045165,cell fate commitment,M110,2,0
1,1,0,-2.6,-3,0,GO:0017015,regulation of transforming growth factor beta receptor signaling pathway,M110,2,0
1,1,0,-4.7,-3.5,0,GO:0046637,regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-4.7,-2.2,0,M122,PID IL2 1PATHWAY,M110,2,0
1,0,1,-3.3,0,-2.1,GO:0043434,response to peptide hormone,M101,2,0
1,1,0,-2,-5.1,0,R-HSA-9824443,Parasitic Infection Pathways,M110,2,0
1,1,0,-3.4,-2.1,0,hsa05224,Breast cancer,M110,2,0
1,0,0,-2.3,0,0,GO:0021545,cranial nerve development,M100,1,0
1,0,0,-3.7,0,0,GO:0032350,regulation of hormone metabolic process,M100,1,0
0,1,0,0,-2.6,0,WP4357,NRF2 ARE regulation,M010,1,0
1,0,0,-2.5,0,0,R-HSA-170834,Signaling by TGF-beta Receptor Complex,M100,1,0
1,0,0,-3.4,0,0,GO:0032526,response to retinoic acid,M100,1,0
1,0,0,-2.8,0,0,GO:1903671,negative regulation of sprouting angiogenesis,M100,1,0
1,0,0,-2.7,0,0,M135,PID IL5 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9823739,Formation of the anterior neural plate,M100,1,0
0,1,0,0,-2.2,0,GO:0060271,cilium assembly,M010,1,0
1,0,0,-3,0,0,GO:0045665,negative regulation of neuron differentiation,M100,1,0
0,1,0,0,-2.6,0,WP2263,Androgen receptor network in prostate cancer,M010,1,0
0,0,1,0,0,-3.9,GO:0032733,positive regulation of interleukin-10 production,M001,1,0
1,0,0,-2,0,0,R-HSA-112040,G-protein mediated events,M100,1,0
0,1,0,0,-2.1,0,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M010,1,0
1,0,0,-2.8,0,0,WP2877,Vitamin D receptor pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0051100,negative regulation of binding,M100,1,0
1,0,0,-2.6,0,0,GO:0001914,regulation of T cell mediated cytotoxicity,M100,1,0
1,0,0,-2.2,0,0,GO:1904036,negative regulation of epithelial cell apoptotic process,M100,1,0
1,0,0,-3.6,0,0,GO:0071375,cellular response to peptide hormone stimulus,M100,1,0
0,1,0,0,-3.7,0,GO:0032102,negative regulation of response to external stimulus,M010,1,0
1,0,0,-4.6,0,0,GO:0062012,regulation of small molecule metabolic process,M100,1,0
1,0,0,-2.2,0,0,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M100,1,0
1,0,0,-2.5,0,0,hsa04931,Insulin resistance,M100,1,0
1,0,0,-2.1,0,0,GO:0061326,renal tubule development,M100,1,0
1,0,0,-4.7,0,0,GO:0007369,gastrulation,M100,1,0
1,0,0,-2.7,0,0,GO:0002714,positive regulation of B cell mediated immunity,M100,1,0
1,0,0,-3,0,0,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M100,1,0
1,0,0,-2,0,0,WP5095,Overview of proinflammatory and profibrotic mediators,M100,1,0
1,0,0,-2.1,0,0,WP5382,TGF Smad signaling pathway,M100,1,0
1,0,0,-2.2,0,0,WP5180,DYRK1A involvement regarding cell proliferation in brain development,M100,1,0
1,0,0,-3.5,0,0,R-HSA-157118,Signaling by NOTCH,M100,1,0
1,0,0,-8.2,0,0,GO:0048705,skeletal system morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:0002091,negative regulation of receptor internalization,M100,1,0
0,1,0,0,-2.1,0,GO:1902882,regulation of response to oxidative stress,M010,1,0
1,0,0,-2.7,0,0,GO:0071104,response to interleukin-9,M100,1,0
1,0,0,-2.4,0,0,GO:1901861,regulation of muscle tissue development,M100,1,0
1,0,0,-6.4,0,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M100,1,0
1,0,0,-2.6,0,0,R-HSA-9006335,Signaling by Erythropoietin,M100,1,0
1,0,0,-4.1,0,0,WP4313,Ferroptosis,M100,1,0
1,0,0,-2.4,0,0,WP4674,Head and neck squamous cell carcinoma,M100,1,0
1,0,0,-3.4,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M100,1,0
1,0,0,-2.8,0,0,hsa05205,Proteoglycans in cancer,M100,1,0
1,0,0,-2.6,0,0,R-HSA-2559580,Oxidative Stress Induced Senescence,M100,1,0
0,1,0,0,-2.2,0,GO:1990858,cellular response to lectin,M010,1,0
1,0,0,-4.3,0,0,R-HSA-9679506,SARS-CoV Infections,M100,1,0
1,0,0,-2.4,0,0,GO:0034599,cellular response to oxidative stress,M100,1,0
1,0,0,-2,0,0,GO:0038110,interleukin-2-mediated signaling pathway,M100,1,0
1,0,0,-3.1,0,0,WP2332,Interleukin 11 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,R-HSA-3304356,SMAD2/3 Phosphorylation Motif Mutants in Cancer,M100,1,0
1,0,0,-4.3,0,0,hsa05162,Measles,M100,1,0
1,0,0,-3.1,0,0,M68,PID RHOA REG PATHWAY,M100,1,0
1,0,0,-8.1,0,0,GO:0001649,osteoblast differentiation,M100,1,0
1,0,0,-5.1,0,0,GO:0031341,regulation of cell killing,M100,1,0
1,0,0,-2.1,0,0,R-HSA-3656534,Loss of Function of TGFBR1 in Cancer,M100,1,0
1,0,0,-2,0,0,GO:1902869,regulation of amacrine cell differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:0050679,positive regulation of epithelial cell proliferation,M100,1,0
1,0,0,-2.7,0,0,GO:0035771,interleukin-4-mediated signaling pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0060396,growth hormone receptor signaling pathway,M100,1,0
1,0,0,-3.2,0,0,WP4496,Signal transduction through IL1R,M100,1,0
1,0,0,-2.7,0,0,GO:0071355,cellular response to interleukin-9,M100,1,0
1,0,0,-3.5,0,0,GO:0051148,negative regulation of muscle cell differentiation,M100,1,0
1,0,0,-2.1,0,0,R-HSA-8854691,Interleukin-20 family signaling,M100,1,0
0,1,0,0,-2.2,0,GO:0046457,prostanoid biosynthetic process,M010,1,0
1,0,0,-2.6,0,0,GO:0016525,negative regulation of angiogenesis,M100,1,0
0,0,1,0,0,-2.7,GO:0051051,negative regulation of transport,M001,1,0
1,0,0,-2,0,0,R-HSA-2025928,Calcineurin activates NFAT,M100,1,0
0,0,1,0,0,-2.3,GO:0015718,monocarboxylic acid transport,M001,1,0
1,0,0,-2.3,0,0,GO:0032352,positive regulation of hormone metabolic process,M100,1,0
1,0,0,-2.1,0,0,WP5422,IL 19 signaling pathway map,M100,1,0
1,0,0,-4.3,0,0,GO:0050678,regulation of epithelial cell proliferation,M100,1,0
1,0,0,-2.4,0,0,GO:1903729,regulation of plasma membrane organization,M100,1,0
1,0,0,-2,0,0,R-HSA-1226099,Signaling by FGFR in disease,M100,1,0
1,0,0,-3.8,0,0,WP2034,Leptin signaling pathway,M100,1,0
1,0,0,-3.6,0,0,M270,PID MAPK TRK PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0042306,regulation of protein import into nucleus,M100,1,0
0,1,0,0,-2.2,0,R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,M010,1,0
1,0,0,-3.1,0,0,GO:0009896,positive regulation of catabolic process,M100,1,0
1,0,0,-2,0,0,GO:0042269,regulation of natural killer cell mediated cytotoxicity,M100,1,0
1,0,0,-3.5,0,0,hsa05160,Hepatitis C,M100,1,0
1,0,0,-2,0,0,CORUM:1519,IL6ST-PRKCD-STAT3 complex,M100,1,0
1,0,0,-5.4,0,0,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M100,1,0
1,0,0,-2.2,0,0,GO:0050994,regulation of lipid catabolic process,M100,1,0
0,1,0,0,-2.1,0,GO:0071277,cellular response to calcium ion,M010,1,0
1,0,0,-4,0,0,R-HSA-9707616,Heme signaling,M100,1,0
1,0,0,-5.4,0,0,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M100,1,0
1,0,0,-2.9,0,0,GO:0021846,cell proliferation in forebrain,M100,1,0
0,1,0,0,-2.1,0,GO:0071346,cellular response to type II interferon,M010,1,0
0,1,0,0,-2,0,GO:0090322,regulation of superoxide metabolic process,M010,1,0
1,0,0,-2.6,0,0,GO:0051151,negative regulation of smooth muscle cell differentiation,M100,1,0
1,0,0,-2.2,0,0,M34,PID TCR PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0036303,lymph vessel morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:0090207,regulation of triglyceride metabolic process,M100,1,0
1,0,0,-2.8,0,0,GO:0097306,cellular response to alcohol,M100,1,0
1,0,0,-3.6,0,0,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M100,1,0
1,0,0,-2.6,0,0,GO:0003180,aortic valve morphogenesis,M100,1,0
1,0,0,-3.7,0,0,GO:0045766,positive regulation of angiogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0031214,biomineral tissue development,M100,1,0
1,0,0,-2.1,0,0,R-HSA-1266695,Interleukin-7 signaling,M100,1,0
1,0,0,-2.2,0,0,GO:0046320,regulation of fatty acid oxidation,M100,1,0
1,0,0,-6.4,0,0,GO:0061351,neural precursor cell proliferation,M100,1,0
1,0,0,-2,0,0,GO:0090403,oxidative stress-induced premature senescence,M100,1,0
1,0,0,-3.4,0,0,hsa04722,Neurotrophin signaling pathway,M100,1,0
0,1,0,0,-2.8,0,GO:0090101,negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M010,1,0
0,1,0,0,-2.4,0,GO:0043306,positive regulation of mast cell degranulation,M010,1,0
1,0,0,-2.2,0,0,R-HSA-73980,RNA Polymerase III Transcription Termination,M100,1,0
0,0,1,0,0,-2.4,GO:0034504,protein localization to nucleus,M001,1,0
1,0,0,-2.9,0,0,hsa04926,Relaxin signaling pathway,M100,1,0
1,0,0,-3.2,0,0,GO:0072132,mesenchyme morphogenesis,M100,1,0
0,1,0,0,-2.7,0,GO:0030833,regulation of actin filament polymerization,M010,1,0
1,0,0,-2.1,0,0,GO:0140546,defense response to symbiont,M100,1,0
1,0,0,-2.6,0,0,GO:0032008,positive regulation of TOR signaling,M100,1,0
1,0,0,-3.9,0,0,GO:0048469,cell maturation,M100,1,0
1,0,0,-4.2,0,0,GO:0019216,regulation of lipid metabolic process,M100,1,0
1,0,0,-4,0,0,GO:0001779,natural killer cell differentiation,M100,1,0
1,0,0,-3,0,0,hsa05134,Legionellosis,M100,1,0
1,0,0,-3,0,0,GO:0045670,regulation of osteoclast differentiation,M100,1,0
1,0,0,-4.8,0,0,GO:0032922,circadian regulation of gene expression,M100,1,0
1,0,0,-5.1,0,0,GO:0120161,regulation of cold-induced thermogenesis,M100,1,0
0,0,1,0,0,-2.3,GO:0048871,multicellular organismal-level homeostasis,M001,1,0
0,0,1,0,0,-3,GO:0008610,lipid biosynthetic process,M001,1,0
1,0,0,-2.8,0,0,GO:0071378,cellular response to growth hormone stimulus,M100,1,0
1,0,0,-2.1,0,0,GO:0010667,negative regulation of cardiac muscle cell apoptotic process,M100,1,0
1,0,0,-2,0,0,R-HSA-8941326,RUNX2 regulates bone development,M100,1,0
0,0,1,0,0,-2.3,GO:0043123,positive regulation of canonical NF-kappaB signal transduction,M001,1,0
1,0,0,-3.7,0,0,GO:1904018,positive regulation of vasculature development,M100,1,0
1,0,0,-2.9,0,0,hsa04810,Regulation of actin cytoskeleton,M100,1,0
0,1,0,0,-4.8,0,WP3612,Photodynamic therapy induced NFE2L2 NRF2 survival signaling,M010,1,0
0,1,0,0,-2.5,0,GO:0030032,lamellipodium assembly,M010,1,0
1,0,0,-2.4,0,0,GO:0021543,pallium development,M100,1,0
1,0,0,-4.3,0,0,GO:0030856,regulation of epithelial cell differentiation,M100,1,0
1,0,0,-4,0,0,GO:0043523,regulation of neuron apoptotic process,M100,1,0
1,0,0,-2,0,0,R-HSA-8939247,RUNX1 regulates transcription of genes involved in interleukin signaling,M100,1,0
1,0,0,-2.1,0,0,WP2261,Glioblastoma signaling pathways,M100,1,0
1,0,0,-2.7,0,0,hsa05165,Human papillomavirus infection,M100,1,0
1,0,0,-8.2,0,0,WP2374,Oncostatin M signaling pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0051224,negative regulation of protein transport,M100,1,0
0,0,1,0,0,-2.7,GO:0032735,positive regulation of interleukin-12 production,M001,1,0
1,0,0,-3.9,0,0,GO:2000736,regulation of stem cell differentiation,M100,1,0
1,0,0,-2,0,0,GO:0032388,positive regulation of intracellular transport,M100,1,0
1,0,0,-2.1,0,0,GO:0006633,fatty acid biosynthetic process,M100,1,0
1,0,0,-2.1,0,0,GO:0032688,negative regulation of interferon-beta production,M100,1,0
1,0,0,-6.3,0,0,GO:0001503,ossification,M100,1,0
1,0,0,-2,0,0,GO:0032747,positive regulation of interleukin-23 production,M100,1,0
1,0,0,-2.4,0,0,M182,PID IL3 PATHWAY,M100,1,0
1,0,0,-5,0,0,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M100,1,0
0,0,1,0,0,-3.2,GO:0008654,phospholipid biosynthetic process,M001,1,0
0,1,0,0,-2.2,0,GO:0050848,regulation of calcium-mediated signaling,M010,1,0
1,0,0,-3,0,0,WP1591,Heart development,M100,1,0
1,0,0,-2.7,0,0,GO:0046822,regulation of nucleocytoplasmic transport,M100,1,0
0,0,1,0,0,-4.9,GO:1901503,ether biosynthetic process,M001,1,0
0,1,0,0,-2.4,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M010,1,0
0,1,0,0,-3.7,0,R-HSA-9664417,Leishmania phagocytosis,M010,1,0
0,1,0,0,-2.4,0,M275,PID ALPHA SYNUCLEIN PATHWAY,M010,1,0
1,0,0,-2.6,0,0,GO:0050868,negative regulation of T cell activation,M100,1,0
1,0,0,-2.4,0,0,hsa05211,Renal cell carcinoma,M100,1,0
1,0,0,-2.2,0,0,WP4566,Translation inhibitors in chronically activated PDGFRA cells,M100,1,0
1,0,0,-2,0,0,GO:0071351,cellular response to interleukin-18,M100,1,0
1,0,0,-2,0,0,GO:0035655,interleukin-18-mediated signaling pathway,M100,1,0
1,0,0,-3.3,0,0,GO:0007440,foregut morphogenesis,M100,1,0
1,0,0,-3.5,0,0,GO:0150063,visual system development,M100,1,0
1,0,0,-3.6,0,0,M36,PID IL27 PATHWAY,M100,1,0
0,1,0,0,-3,0,WP98,Prostaglandin synthesis and regulation,M010,1,0
1,0,0,-2.1,0,0,WP4941,GPR143 in melanocytes and retinal pigment epithelium cells,M100,1,0
0,1,0,0,-2.8,0,R-HSA-202733,Cell surface interactions at the vascular wall,M010,1,0
1,0,0,-2.2,0,0,GO:0048010,vascular endothelial growth factor receptor signaling pathway,M100,1,0
1,0,0,-3.6,0,0,GO:0035136,forelimb morphogenesis,M100,1,0
1,0,0,-2.2,0,0,WP3915,Angiopoietin like protein 8 regulatory pathway,M100,1,0
0,1,0,0,-2.1,0,R-HSA-2029481,FCGR activation,M010,1,0
1,0,0,-6.4,0,0,GO:0001568,blood vessel development,M100,1,0
1,0,0,-2,0,0,M231,PID KIT PATHWAY,M100,1,0
1,0,0,-5.4,0,0,GO:0043255,regulation of carbohydrate biosynthetic process,M100,1,0
1,0,0,-2,0,0,GO:0048635,negative regulation of muscle organ development,M100,1,0
1,0,0,-3.6,0,0,WP5098,T cell activation SARS CoV 2,M100,1,0
1,0,0,-4,0,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M100,1,0
1,0,0,-2.5,0,0,hsa04929,GnRH secretion,M100,1,0
1,0,0,-5.6,0,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M100,1,0
1,0,0,-2.1,0,0,GO:0046533,negative regulation of photoreceptor cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0042476,odontogenesis,M100,1,0
1,0,0,-2.7,0,0,R-HSA-8951936,RUNX3 regulates p14-ARF,M100,1,0
1,0,0,-3.3,0,0,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M100,1,0
1,0,0,-2.6,0,0,GO:0035272,exocrine system development,M100,1,0
1,0,0,-3.2,0,0,WP304,Kit receptor signaling pathway,M100,1,0
1,0,0,-2.8,0,0,hsa05150,Staphylococcus aureus infection,M100,1,0
1,0,0,-2,0,0,GO:0030953,astral microtubule organization,M100,1,0
1,0,0,-4.5,0,0,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M100,1,0
1,0,0,-3.6,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M100,1,0
0,0,1,0,0,-3.2,GO:0060907,positive regulation of macrophage cytokine production,M001,1,0
1,0,0,-2.1,0,0,GO:0072537,fibroblast activation,M100,1,0
1,0,0,-2.7,0,0,GO:0010638,positive regulation of organelle organization,M100,1,0
1,0,0,-2.1,0,0,R-HSA-8939245,RUNX1 regulates transcription of genes involved in BCR signaling,M100,1,0
1,0,0,-2.6,0,0,GO:0016032,viral process,M100,1,0
1,0,0,-2.8,0,0,GO:0071496,cellular response to external stimulus,M100,1,0
1,0,0,-3.2,0,0,M285,PID HNF3A PATHWAY,M100,1,0
0,1,0,0,-2.9,0,GO:0032663,regulation of interleukin-2 production,M010,1,0
1,0,0,-3.2,0,0,hsa05223,Non-small cell lung cancer,M100,1,0
1,0,0,-2.1,0,0,CORUM:642,CtBP complex,M100,1,0
1,0,0,-3.8,0,0,GO:0035113,embryonic appendage morphogenesis,M100,1,0
1,0,0,-2.7,0,0,GO:0046903,secretion,M100,1,0
1,0,0,-2.2,0,0,WP205,IL 7 signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0050768,negative regulation of neurogenesis,M100,1,0
0,1,0,0,-2.7,0,WP2873,Aryl hydrocarbon receptor pathway,M010,1,0
1,0,0,-3.3,0,0,GO:0034616,response to laminar fluid shear stress,M100,1,0
0,1,0,0,-2.9,0,GO:0032743,positive regulation of interleukin-2 production,M010,1,0
1,0,0,-2.7,0,0,GO:0032386,regulation of intracellular transport,M100,1,0
1,0,0,-3.4,0,0,WP4842,Mammalian disorder of sexual development,M100,1,0
1,0,0,-2.6,0,0,GO:0035116,embryonic hindlimb morphogenesis,M100,1,0
1,0,0,-7.5,0,0,GO:1904888,cranial skeletal system development,M100,1,0
1,0,0,-2.6,0,0,M58,PID AR PATHWAY,M100,1,0
1,0,0,-4.5,0,0,GO:0002705,positive regulation of leukocyte mediated immunity,M100,1,0
1,0,0,-5.2,0,0,WP2526,PDGF pathway,M100,1,0
1,0,0,-3.2,0,0,GO:0043030,regulation of macrophage activation,M100,1,0
1,0,0,-2.7,0,0,GO:0002679,respiratory burst involved in defense response,M100,1,0
0,1,0,0,-3.9,0,R-HSA-9664420,Killing mechanisms,M010,1,0
1,0,0,-2.6,0,0,GO:0043524,negative regulation of neuron apoptotic process,M100,1,0
1,0,0,-2.2,0,0,GO:0110053,regulation of actin filament organization,M100,1,0
1,0,0,-2.4,0,0,hsa04066,HIF-1 signaling pathway,M100,1,0
0,0,1,0,0,-2.3,GO:0006814,sodium ion transport,M001,1,0
1,0,0,-3.9,0,0,GO:0070167,regulation of biomineral tissue development,M100,1,0
1,0,0,-3.8,0,0,hsa04650,Natural killer cell mediated cytotoxicity,M100,1,0
0,0,1,0,0,-2.4,GO:0010232,vascular transport,M001,1,0
1,0,0,-2,0,0,GO:0030330,"DNA damage response, signal transduction by p53 class mediator",M100,1,0
1,0,0,-2.1,0,0,WP5094,Orexin receptor pathway,M100,1,0
0,0,1,0,0,-2.8,GO:0006650,glycerophospholipid metabolic process,M001,1,0
1,0,0,-2.6,0,0,GO:0010717,regulation of epithelial to mesenchymal transition,M100,1,0
1,0,0,-3.7,0,0,GO:0030501,positive regulation of bone mineralization,M100,1,0
1,0,0,-2.9,0,0,GO:1905153,regulation of membrane invagination,M100,1,0
1,0,0,-3.9,0,0,hsa05203,Viral carcinogenesis,M100,1,0
0,1,0,0,-2.2,0,GO:0001516,prostaglandin biosynthetic process,M010,1,0
1,0,0,-5.1,0,0,WP3972,PDGFR beta pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0048771,tissue remodeling,M100,1,0
0,1,0,0,-2.4,0,WP363,Wnt signaling pathway,M010,1,0
1,0,0,-5.8,0,0,GO:0032774,RNA biosynthetic process,M100,1,0
1,0,0,-2,0,0,WP1971,Integrated cancer pathway,M100,1,0
0,1,0,0,-2.9,0,WP3953,mRNA protein and metabolite inducation pathway by cyclosporin A,M010,1,0
1,0,0,-2.1,0,0,R-HSA-194138,Signaling by VEGF,M100,1,0
0,1,0,0,-2.4,0,GO:0060252,positive regulation of glial cell proliferation,M010,1,0
0,1,0,0,-3.3,0,GO:0050854,regulation of antigen receptor-mediated signaling pathway,M010,1,0
1,0,0,-3.1,0,0,M254,PID MYC REPRESS PATHWAY,M100,1,0
1,0,0,-5.8,0,0,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M100,1,0
1,0,0,-2.9,0,0,GO:0140888,interferon-mediated signaling pathway,M100,1,0
1,0,0,-3.9,0,0,GO:1901653,cellular response to peptide,M100,1,0
1,0,0,-3.6,0,0,GO:0048589,developmental growth,M100,1,0
1,0,0,-2.2,0,0,GO:0002709,regulation of T cell mediated immunity,M100,1,0
0,1,0,0,-2.2,0,GO:0043032,positive regulation of macrophage activation,M010,1,0
1,0,0,-2.6,0,0,WP4538,Regulatory circuits of the STAT3 signaling pathway,M100,1,0
1,0,0,-3.8,0,0,R-HSA-877300,Interferon gamma signaling,M100,1,0
1,0,0,-2.3,0,0,GO:0048339,paraxial mesoderm development,M100,1,0
1,0,0,-3.2,0,0,GO:0048565,digestive tract development,M100,1,0
1,0,0,-2.1,0,0,WP4269,Ethanol metabolism production of ROS by CYP2E1,M100,1,0
1,0,0,-2.2,0,0,hsa04612,Antigen processing and presentation,M100,1,0
1,0,0,-2.8,0,0,GO:0001707,mesoderm formation,M100,1,0
0,1,0,0,-2.2,0,GO:0007599,hemostasis,M010,1,0
1,0,0,-3.4,0,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M100,1,0
1,0,0,-2.6,0,0,R-HSA-1839124,FGFR1 mutant receptor activation,M100,1,0
1,0,0,-2.8,0,0,WP2881,Estrogen receptor pathway,M100,1,0
1,0,0,-4,0,0,M54,PID IL12 2PATHWAY,M100,1,0
1,0,0,-2.2,0,0,R-HSA-112043,PLC beta mediated events,M100,1,0
1,0,0,-3.4,0,0,R-HSA-1368082,RORA activates gene expression,M100,1,0
1,0,0,-2,0,0,R-HSA-8849473,PTK6 Expression,M100,1,0
1,0,0,-2.7,0,0,GO:0071499,cellular response to laminar fluid shear stress,M100,1,0
0,1,0,0,-2.9,0,WP4928,MAPK pathway in congenital thyroid cancer,M010,1,0
1,0,0,-3.4,0,0,R-HSA-9018519,Estrogen-dependent gene expression,M100,1,0
1,0,0,-2.8,0,0,hsa04390,Hippo signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0090287,regulation of cellular response to growth factor stimulus,M010,1,0
0,1,0,0,-2.9,0,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M010,1,0
1,0,0,-2.2,0,0,WP1991,SRF and miRs in smooth muscle differentiation and proliferation,M100,1,0
1,0,0,-2.3,0,0,GO:0003143,embryonic heart tube morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0035590,purinergic nucleotide receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0060828,regulation of canonical Wnt signaling pathway,M100,1,0
1,0,0,-3.1,0,0,R-HSA-186763,Downstream signal transduction,M100,1,0
1,0,0,-2.6,0,0,GO:1901343,negative regulation of vasculature development,M100,1,0
1,0,0,-4.8,0,0,GO:0010001,glial cell differentiation,M100,1,0
1,0,0,-2.3,0,0,GO:0032652,regulation of interleukin-1 production,M100,1,0
1,0,0,-3.4,0,0,GO:0051101,regulation of DNA binding,M100,1,0
1,0,0,-7,0,0,GO:0061448,connective tissue development,M100,1,0
1,0,0,-2.8,0,0,GO:0002293,alpha-beta T cell differentiation involved in immune response,M100,1,0
1,0,0,-2.2,0,0,R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,M100,1,0
1,0,0,-3.4,0,0,GO:0030036,actin cytoskeleton organization,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,M100,1,0
0,1,0,0,-3,0,GO:0030512,negative regulation of transforming growth factor beta receptor signaling pathway,M010,1,0
0,1,0,0,-3.2,0,M8,PID ENDOTHELIN PATHWAY,M010,1,0
1,0,0,-2.8,0,0,M100,PID SHP2 PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:0071674,mononuclear cell migration,M100,1,0
1,0,0,-4.8,0,0,hsa05142,Chagas disease,M100,1,0
1,0,0,-2,0,0,GO:0060441,epithelial tube branching involved in lung morphogenesis,M100,1,0
1,0,0,-3,0,0,GO:0042692,muscle cell differentiation,M100,1,0
0,1,0,0,-3.3,0,GO:0060368,regulation of Fc receptor mediated stimulatory signaling pathway,M010,1,0
1,0,0,-2.5,0,0,GO:0031334,positive regulation of protein-containing complex assembly,M100,1,0
1,0,0,-2.2,0,0,GO:0048260,positive regulation of receptor-mediated endocytosis,M100,1,0
1,0,0,-2,0,0,M162,PID RXR VDR PATHWAY,M100,1,0
1,0,0,-3.1,0,0,M32,PID HDAC CLASSIII PATHWAY,M100,1,0
1,0,0,-3.8,0,0,GO:0030326,embryonic limb morphogenesis,M100,1,0
1,0,0,-2.1,0,0,WP4321,Thermogenesis,M100,1,0
0,0,1,0,0,-2.1,GO:0098739,import across plasma membrane,M001,1,0
0,0,1,0,0,-2.2,GO:0015711,organic anion transport,M001,1,0
1,0,0,-3,0,0,WP170,Nuclear receptors,M100,1,0
1,0,0,-2.5,0,0,GO:0010506,regulation of autophagy,M100,1,0
1,0,0,-2.6,0,0,R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,M100,1,0
1,0,0,-3.1,0,0,GO:0036075,replacement ossification,M100,1,0
1,0,0,-2.8,0,0,GO:0070102,interleukin-6-mediated signaling pathway,M100,1,0
1,0,0,-2,0,0,hsa05226,Gastric cancer,M100,1,0
1,0,0,-2,0,0,GO:0001945,lymph vessel development,M100,1,0
1,0,0,-3.2,0,0,WP4217,Ebola virus infection in host,M100,1,0
0,0,1,0,0,-4.3,GO:0032653,regulation of interleukin-10 production,M001,1,0
1,0,0,-2.1,0,0,CORUM:3045,hs4 enhancer complex (faster migrating complex),M100,1,0
0,1,0,0,-3.5,0,GO:2000106,regulation of leukocyte apoptotic process,M010,1,0
1,0,0,-12,0,0,GO:0071407,cellular response to organic cyclic compound,M100,1,0
1,0,0,-2.6,0,0,GO:0042088,T-helper 1 type immune response,M100,1,0
0,1,0,0,-2.1,0,GO:0045859,regulation of protein kinase activity,M010,1,0
1,0,0,-2,0,0,GO:0062014,negative regulation of small molecule metabolic process,M100,1,0
1,0,0,-2.6,0,0,R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,M100,1,0
1,0,0,-2.3,0,0,GO:0043392,negative regulation of DNA binding,M100,1,0
1,0,0,-2.4,0,0,R-HSA-3232118,SUMOylation of transcription factors,M100,1,0
0,0,1,0,0,-2.2,GO:0002221,pattern recognition receptor signaling pathway,M001,1,0
1,0,0,-2,0,0,GO:0032667,regulation of interleukin-23 production,M100,1,0
1,0,0,-2.7,0,0,M190,PID TCR JNK PATHWAY,M100,1,0
1,0,0,-3.3,0,0,WP481,Insulin signaling,M100,1,0
1,0,0,-2.1,0,0,GO:0042119,neutrophil activation,M100,1,0
1,0,0,-2.7,0,0,WP2276,Glial cell differentiation,M100,1,0
1,0,0,-2,0,0,CORUM:5260,TCF4-CTNNB1-SUMO1-EP300-HADAC6 complex,M100,1,0
1,0,0,-4.4,0,0,GO:0048863,stem cell differentiation,M100,1,0
0,1,0,0,-3,0,GO:0045197,establishment or maintenance of epithelial cell apical/basal polarity,M010,1,0
1,0,0,-2,0,0,GO:0060662,salivary gland cavitation,M100,1,0
0,1,0,0,-3.3,0,GO:1900029,positive regulation of ruffle assembly,M010,1,0
0,1,0,0,-2.5,0,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M010,1,0
1,0,0,-2.9,0,0,R-HSA-9006925,Intracellular signaling by second messengers,M100,1,0
1,0,0,-2.1,0,0,GO:0051851,modulation by host of symbiont process,M100,1,0
1,0,0,-3.4,0,0,GO:0045912,negative regulation of carbohydrate metabolic process,M100,1,0
1,0,0,-2.2,0,0,GO:0002090,regulation of receptor internalization,M100,1,0
1,0,0,-4.3,0,0,GO:0001704,formation of primary germ layer,M100,1,0
1,0,0,-3.3,0,0,WP195,IL 1 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0045060,negative thymic T cell selection,M100,1,0
1,0,0,-2.5,0,0,GO:0071354,cellular response to interleukin-6,M100,1,0
1,0,0,-8.6,0,0,GO:0071363,cellular response to growth factor stimulus,M100,1,0
1,0,0,-2.9,0,0,GO:0042129,regulation of T cell proliferation,M100,1,0
0,0,1,0,0,-2.4,GO:0150104,transport across blood-brain barrier,M001,1,0
1,0,0,-2.6,0,0,WP4331,Neovascularisation processes,M100,1,0
1,0,0,-2.6,0,0,GO:0048762,mesenchymal cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0010936,negative regulation of macrophage cytokine production,M100,1,0
1,0,0,-6.5,0,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M100,1,0
1,0,0,-3,0,0,GO:0032722,positive regulation of chemokine production,M100,1,0
1,0,0,-6.2,0,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M100,1,0
1,0,0,-2.9,0,0,hsa04216,Ferroptosis,M100,1,0
1,0,0,-2.5,0,0,GO:0050900,leukocyte migration,M100,1,0
1,0,0,-2.9,0,0,GO:0070741,response to interleukin-6,M100,1,0
1,0,0,-6.1,0,0,GO:0002062,chondrocyte differentiation,M100,1,0
1,0,0,-4.7,0,0,hsa04350,TGF-beta signaling pathway,M100,1,0
1,0,0,-2,0,0,CORUM:1816,JUN-TCF4-CTNNB1 complex,M100,1,0
1,0,0,-5.7,0,0,GO:1902894,negative regulation of miRNA transcription,M100,1,0
1,0,0,-2,0,0,GO:0098868,bone growth,M100,1,0
1,0,0,-2.1,0,0,M175,PID ERBB2 ERBB3 PATHWAY,M100,1,0
1,0,0,-4.4,0,0,WP400,p38 MAPK signaling pathway,M100,1,0
1,0,0,-2.9,0,0,GO:0007272,ensheathment of neurons,M100,1,0
1,0,0,-2.1,0,0,GO:0072126,positive regulation of glomerular mesangial cell proliferation,M100,1,0
1,0,0,-2.1,0,0,R-HSA-2586552,Signaling by Leptin,M100,1,0
1,0,0,-3.1,0,0,GO:0001958,endochondral ossification,M100,1,0
1,0,0,-2.7,0,0,R-HSA-400508,"Incretin synthesis, secretion, and inactivation",M100,1,0
1,0,0,-3.1,0,0,R-HSA-446652,Interleukin-1 family signaling,M100,1,0
1,0,0,-3,0,0,WP4754,IL 18 signaling pathway,M100,1,0
1,0,0,-2.7,0,0,GO:0048385,regulation of retinoic acid receptor signaling pathway,M100,1,0
1,0,0,-3.1,0,0,R-HSA-525793,Myogenesis,M100,1,0
0,1,0,0,-2.6,0,R-HSA-9029558,NR1H2 & NR1H3 regulate gene expression linked to lipogenesis,M010,1,0
1,0,0,-2,0,0,WP3674,Tgif disruption of Shh signaling,M100,1,0
1,0,0,-2.6,0,0,WP3303,RAC1 PAK1 p38 MMP2 pathway,M100,1,0
1,0,0,-4.5,0,0,GO:0072091,regulation of stem cell proliferation,M100,1,0
1,0,0,-3.6,0,0,hsa04668,TNF signaling pathway,M100,1,0
0,0,1,0,0,-2.1,GO:0043065,positive regulation of apoptotic process,M001,1,0
1,0,0,-2.2,0,0,GO:1905523,positive regulation of macrophage migration,M100,1,0
1,0,0,-3,0,0,hsa04917,Prolactin signaling pathway,M100,1,0
1,0,0,-2.2,0,0,WP4814,Somatic sex determination,M100,1,0
1,0,0,-2,0,0,GO:0035283,central nervous system segmentation,M100,1,0
0,1,0,0,-2.2,0,GO:0061842,microtubule organizing center localization,M010,1,0
1,0,0,-2.1,0,0,GO:2000379,positive regulation of reactive oxygen species metabolic process,M100,1,0
1,0,0,-2,0,0,CORUM:5261,TCF4-CTNNB1-EP300 complex,M100,1,0
0,1,0,0,-2.3,0,GO:0045936,negative regulation of phosphate metabolic process,M010,1,0
1,0,0,-2.5,0,0,R-HSA-2990846,SUMOylation,M100,1,0
1,0,0,-3,0,0,WP364,IL6 signaling pathway,M100,1,0
1,0,0,-5.9,0,0,hsa05321,Inflammatory bowel disease,M100,1,0
1,0,0,-2.1,0,0,GO:0010517,regulation of phospholipase activity,M100,1,0
1,0,0,-4,0,0,GO:0009952,anterior/posterior pattern specification,M100,1,0
1,0,0,-2.4,0,0,GO:0010883,regulation of lipid storage,M100,1,0
1,0,0,-3.1,0,0,GO:0071675,regulation of mononuclear cell migration,M100,1,0
1,0,0,-2,0,0,CORUM:7534,CTNNB1-EPCAM-FHL2-LEF1 complex,M100,1,0
1,0,0,-2.6,0,0,GO:0098727,maintenance of cell number,M100,1,0
1,0,0,-2.1,0,0,GO:0051091,positive regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.3,0,0,GO:0009247,glycolipid biosynthetic process,M100,1,0
1,0,0,-4.2,0,0,GO:0043254,regulation of protein-containing complex assembly,M100,1,0
1,0,0,-3,0,0,GO:0048259,regulation of receptor-mediated endocytosis,M100,1,0
1,0,0,-3.2,0,0,GO:0002067,glandular epithelial cell differentiation,M100,1,0
1,0,0,-3.6,0,0,GO:2000351,regulation of endothelial cell apoptotic process,M100,1,0
0,1,0,0,-2.4,0,GO:0072189,ureter development,M010,1,0
1,0,0,-4.5,0,0,R-HSA-9006931,Signaling by Nuclear Receptors,M100,1,0
1,0,0,-3,0,0,WP2858,Ectoderm differentiation,M100,1,0
1,0,0,-3.5,0,0,R-HSA-8980692,RHOA GTPase cycle,M100,1,0
1,0,0,-3.7,0,0,GO:0002720,positive regulation of cytokine production involved in immune response,M100,1,0
1,0,0,-3.1,0,0,R-HSA-1433557,Signaling by SCF-KIT,M100,1,0
1,0,0,-4,0,0,GO:0021781,glial cell fate commitment,M100,1,0
1,0,0,-4.4,0,0,GO:0048545,response to steroid hormone,M100,1,0
0,1,0,0,-2.8,0,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-3.1,0,0,GO:0030323,respiratory tube development,M100,1,0
1,0,0,-2.3,0,0,hsa04622,RIG-I-like receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9703465,Signaling by FLT3 fusion proteins,M100,1,0
0,1,0,0,-3.1,0,hsa05130,Pathogenic Escherichia coli infection,M010,1,0
1,0,0,-2.8,0,0,GO:0002711,positive regulation of T cell mediated immunity,M100,1,0
1,0,0,-2,0,0,GO:0010665,regulation of cardiac muscle cell apoptotic process,M100,1,0
1,0,0,-2.8,0,0,WP1541,Energy metabolism,M100,1,0
1,0,0,-2.1,0,0,R-HSA-8934593,Regulation of RUNX1 Expression and Activity,M100,1,0
1,0,0,-2.6,0,0,GO:0071677,positive regulation of mononuclear cell migration,M100,1,0
1,0,0,-4,0,0,GO:0035108,limb morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:0072171,mesonephric tubule morphogenesis,M100,1,0
1,0,0,-2.6,0,0,GO:0006898,receptor-mediated endocytosis,M100,1,0
1,0,0,-2.2,0,0,R-HSA-6783589,Interleukin-6 family signaling,M100,1,0
0,1,0,0,-3.2,0,GO:0043304,regulation of mast cell degranulation,M010,1,0
1,0,0,-2.5,0,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-5.1,0,0,GO:0003002,regionalization,M100,1,0
1,0,0,-5.8,0,0,hsa05152,Tuberculosis,M100,1,0
1,0,0,-2.1,0,0,WP1772,Apoptosis modulation and signaling,M100,1,0
1,0,0,-2.4,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M100,1,0
0,1,0,0,-2.2,0,WP3942,PPAR signaling pathway,M010,1,0
0,1,0,0,-2.1,0,GO:0099170,postsynaptic modulation of chemical synaptic transmission,M010,1,0
1,0,0,-2.2,0,0,GO:0007264,small GTPase mediated signal transduction,M100,1,0
0,1,0,0,-2.9,0,GO:0090184,positive regulation of kidney development,M010,1,0
1,0,0,-6.4,0,0,GO:0001944,vasculature development,M100,1,0
0,1,0,0,-4.8,0,R-HSA-109582,Hemostasis,M010,1,0
1,0,0,-2.2,0,0,GO:0030866,cortical actin cytoskeleton organization,M100,1,0
1,0,0,-2.7,0,0,GO:0070669,response to interleukin-2,M100,1,0
1,0,0,-2.1,0,0,WP1528,Physiological and pathological hypertrophy of the heart,M100,1,0
1,0,0,-2,0,0,GO:0003430,growth plate cartilage chondrocyte growth,M100,1,0
1,0,0,-2.4,0,0,GO:0046890,regulation of lipid biosynthetic process,M100,1,0
1,0,0,-3.2,0,0,WP4541,Hippo Merlin signaling dysregulation,M100,1,0
1,0,0,-2,0,0,GO:0046469,platelet activating factor metabolic process,M100,1,0
1,0,0,-3.6,0,0,hsa04640,Hematopoietic cell lineage,M100,1,0
1,0,0,-2,0,0,GO:0022604,regulation of cell morphogenesis,M100,1,0
1,0,0,-3.3,0,0,M44,PID HIF2PATHWAY,M100,1,0
1,0,0,-4.4,0,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M100,1,0
0,1,0,0,-3.7,0,R-HSA-9664422,FCGR3A-mediated phagocytosis,M010,1,0
1,0,0,-4.5,0,0,GO:0002824,positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
1,0,0,-2.5,0,0,GO:0046632,alpha-beta T cell differentiation,M100,1,0
1,0,0,-3.2,0,0,GO:0048806,genitalia development,M100,1,0
1,0,0,-2.7,0,0,GO:0046321,positive regulation of fatty acid oxidation,M100,1,0
0,1,0,0,-2.4,0,M76,PID P38 ALPHA BETA PATHWAY,M010,1,0
1,0,0,-2.6,0,0,GO:1900024,regulation of substrate adhesion-dependent cell spreading,M100,1,0
1,0,0,-3.6,0,0,GO:0071695,anatomical structure maturation,M100,1,0
1,0,0,-2.7,0,0,R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",M100,1,0
1,0,0,-2.1,0,0,GO:0045620,negative regulation of lymphocyte differentiation,M100,1,0
1,0,0,-2,0,0,GO:0060605,tube lumen cavitation,M100,1,0
1,0,0,-2,0,0,GO:0071593,lymphocyte aggregation,M100,1,0
1,0,0,-2.7,0,0,GO:0071774,response to fibroblast growth factor,M100,1,0
0,1,0,0,-2.1,0,GO:0002861,regulation of inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-2.1,0,0,GO:2000977,regulation of forebrain neuron differentiation,M100,1,0
1,0,0,-3.3,0,0,GO:0031329,regulation of cellular catabolic process,M100,1,0
0,1,0,0,-2.6,0,R-HSA-354192,Integrin signaling,M010,1,0
1,0,0,-2.1,0,0,GO:0006164,purine nucleotide biosynthetic process,M100,1,0
1,0,0,-2.8,0,0,R-HSA-451927,Interleukin-2 family signaling,M100,1,0
0,1,0,0,-2.7,0,GO:1902532,negative regulation of intracellular signal transduction,M010,1,0
1,0,0,-2.4,0,0,GO:0007266,Rho protein signal transduction,M100,1,0
1,0,0,-2.2,0,0,GO:0021532,neural tube patterning,M100,1,0
1,0,0,-2.5,0,0,WP138,Androgen receptor signaling pathway,M100,1,0
1,0,0,-3.3,0,0,GO:0060100,"positive regulation of phagocytosis, engulfment",M100,1,0
1,0,0,-2,0,0,GO:0002309,T cell proliferation involved in immune response,M100,1,0
1,0,0,-2.3,0,0,GO:0072163,mesonephric epithelium development,M100,1,0
1,0,0,-3.3,0,0,R-HSA-6804758,Regulation of TP53 Activity through Acetylation,M100,1,0
1,0,0,-2.2,0,0,GO:0001676,long-chain fatty acid metabolic process,M100,1,0
0,0,1,0,0,-2.6,GO:0044782,cilium organization,M001,1,0
1,0,0,-5.3,0,0,GO:0002699,positive regulation of immune effector process,M100,1,0
1,0,0,-6.8,0,0,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M100,1,0
1,0,0,-2.6,0,0,WP231,TNF alpha signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0048821,erythrocyte development,M100,1,0
1,0,0,-2.8,0,0,GO:0070665,positive regulation of leukocyte proliferation,M100,1,0
1,0,0,-2.1,0,0,GO:0071357,cellular response to type I interferon,M100,1,0
1,0,0,-2.5,0,0,WP4787,Osteoblast differentiation and related diseases,M100,1,0
1,0,0,-3.1,0,0,GO:2000403,positive regulation of lymphocyte migration,M100,1,0
0,1,0,0,-3.7,0,GO:0042832,defense response to protozoan,M010,1,0
1,0,0,-3.6,0,0,M91,PID TCPTP PATHWAY,M100,1,0
1,0,0,-4.1,0,0,WP4630,Measles virus infection,M100,1,0
1,0,0,-6,0,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M100,1,0
1,0,0,-2.8,0,0,GO:0071229,cellular response to acid chemical,M100,1,0
0,1,0,0,-3.2,0,GO:0046633,alpha-beta T cell proliferation,M010,1,0
1,0,0,-2.2,0,0,M236,PID DELTA NP63 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,WP5356,Disturbed pathways in Duchenne Muscular Dystrophy,M100,1,0
1,0,0,-2.5,0,0,GO:0019827,stem cell population maintenance,M100,1,0
1,0,0,-2.3,0,0,GO:0044403,biological process involved in symbiotic interaction,M100,1,0
1,0,0,-3,0,0,GO:0043401,steroid hormone mediated signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0001947,heart looping,M100,1,0
1,0,0,-4.6,0,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M100,1,0
0,1,0,0,-2.2,0,hsa04921,Oxytocin signaling pathway,M010,1,0
1,0,0,-3.8,0,0,R-HSA-9758941,Gastrulation,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9020702,Interleukin-1 signaling,M100,1,0
1,0,0,-6.5,0,0,GO:0042063,gliogenesis,M100,1,0
1,0,0,-2,0,0,GO:0061046,regulation of branching involved in lung morphogenesis,M100,1,0
1,0,0,-3.4,0,0,GO:0002825,regulation of T-helper 1 type immune response,M100,1,0
1,0,0,-4.9,0,0,hsa04936,Alcoholic liver disease,M100,1,0
1,0,0,-4.9,0,0,R-HSA-448424,Interleukin-17 signaling,M100,1,0
0,1,0,0,-2.4,0,GO:0006636,unsaturated fatty acid biosynthetic process,M010,1,0
1,0,0,-2.7,0,0,GO:0002891,positive regulation of immunoglobulin mediated immune response,M100,1,0
0,0,1,0,0,-3.6,GO:0046474,glycerophospholipid biosynthetic process,M001,1,0
1,0,0,-2.9,0,0,GO:0060099,"regulation of phagocytosis, engulfment",M100,1,0
1,0,0,-2.1,0,0,M101,PID HDAC CLASSI PATHWAY,M100,1,0
1,0,0,-3.9,0,0,GO:0022408,negative regulation of cell-cell adhesion,M100,1,0
1,0,0,-2,0,0,GO:0045843,negative regulation of striated muscle tissue development,M100,1,0
1,0,0,-3.6,0,0,GO:0009991,response to extracellular stimulus,M100,1,0
1,0,0,-4.7,0,0,GO:0048754,branching morphogenesis of an epithelial tube,M100,1,0
1,0,0,-2.1,0,0,GO:0033173,calcineurin-NFAT signaling cascade,M100,1,0
0,0,1,0,0,-2.4,GO:0034341,response to type II interferon,M001,1,0
1,0,0,-2.4,0,0,GO:0007548,sex differentiation,M100,1,0
1,0,0,-7.6,0,0,WP5039,SARS CoV 2 innate immunity evasion and cell specific immune response,M100,1,0
1,0,0,-5.8,0,0,hsa04630,JAK-STAT signaling pathway,M100,1,0
1,0,0,-4.6,0,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M100,1,0
1,0,0,-3.3,0,0,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M100,1,0
1,0,0,-2.4,0,0,GO:0032006,regulation of TOR signaling,M100,1,0
1,0,0,-2,0,0,GO:0038154,interleukin-11-mediated signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:0033262,regulation of nuclear cell cycle DNA replication,M100,1,0
1,0,0,-2.4,0,0,GO:0046425,regulation of receptor signaling pathway via JAK-STAT,M100,1,0
0,0,1,0,0,-2.3,GO:0099587,inorganic ion import across plasma membrane,M001,1,0
1,0,0,-2.3,0,0,GO:0033157,regulation of intracellular protein transport,M100,1,0
1,0,0,-5.8,0,0,GO:0048701,embryonic cranial skeleton morphogenesis,M100,1,0
1,0,0,-5,0,0,GO:0045765,regulation of angiogenesis,M100,1,0
1,0,0,-2,0,0,GO:0035306,positive regulation of dephosphorylation,M100,1,0
1,0,0,-2.6,0,0,GO:0036230,granulocyte activation,M100,1,0
1,0,0,-4.2,0,0,hsa05221,Acute myeloid leukemia,M100,1,0
0,1,0,0,-2.2,0,M65,PID FRA PATHWAY,M010,1,0
0,1,0,0,-2.4,0,GO:1901739,regulation of myoblast fusion,M010,1,0
0,0,1,0,0,-3.8,GO:0018904,ether metabolic process,M001,1,0
0,1,0,0,-2.4,0,GO:0001933,negative regulation of protein phosphorylation,M010,1,0
1,0,0,-2.1,0,0,CORUM:2084,NFKB1-NFKB2-REL-RELA-RELB complex,M100,1,0
1,0,0,-3.3,0,0,GO:0060788,ectodermal placode formation,M100,1,0
1,0,0,-2.9,0,0,GO:0032946,positive regulation of mononuclear cell proliferation,M100,1,0
1,0,0,-3.5,0,0,WP3931,Embryonic stem cell pluripotency pathways,M100,1,0
1,0,0,-2.3,0,0,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M100,1,0
1,0,0,-2.1,0,0,GO:0007520,myoblast fusion,M100,1,0
1,0,0,-3.2,0,0,GO:0001709,cell fate determination,M100,1,0
1,0,0,-4.4,0,0,hsa04010,MAPK signaling pathway,M100,1,0
0,1,0,0,-2.6,0,GO:0071248,cellular response to metal ion,M010,1,0
1,0,0,-2.8,0,0,GO:0035050,embryonic heart tube development,M100,1,0
1,0,0,-2.6,0,0,GO:0060438,trachea development,M100,1,0
1,0,0,-8.6,0,0,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M100,1,0
1,0,0,-3.4,0,0,R-HSA-8985947,Interleukin-9 signaling,M100,1,0
1,0,0,-2.1,0,0,R-HSA-1059683,Interleukin-6 signaling,M100,1,0
1,0,0,-2.1,0,0,GO:0045834,positive regulation of lipid metabolic process,M100,1,0
1,0,0,-2.5,0,0,WP3584,MECP2 and associated Rett syndrome,M100,1,0
1,0,0,-2.1,0,0,GO:0014910,regulation of smooth muscle cell migration,M100,1,0
0,1,0,0,-2,0,GO:0051348,negative regulation of transferase activity,M010,1,0
1,0,0,-2,0,0,CORUM:2529,"LAT-PLC-gamma-1-p85-GRB2-CBL-VAV-SLP-76 signaling complex, C305 activated",M100,1,0
1,0,0,-3.7,0,0,WP4329,miRNA role in immune response in sepsis,M100,1,0
1,0,0,-2.8,0,0,GO:2000648,positive regulation of stem cell proliferation,M100,1,0
1,0,0,-3.5,0,0,GO:0002520,immune system development,M100,1,0
1,0,0,-2.3,0,0,GO:0003179,heart valve morphogenesis,M100,1,0
1,0,0,-4.9,0,0,WP2637,Interleukin 1 IL 1 structural pathway,M100,1,0
1,0,0,-3,0,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M100,1,0
1,0,0,-2.8,0,0,GO:0060872,semicircular canal development,M100,1,0
1,0,0,-6.2,0,0,M28,PID IL4 2PATHWAY,M100,1,0
0,1,0,0,-2.1,0,WP2878,PPAR alpha pathway,M010,1,0
0,1,0,0,-2.6,0,hsa04726,Serotonergic synapse,M010,1,0
1,0,0,-3.1,0,0,GO:0070555,response to interleukin-1,M100,1,0
1,0,0,-3.7,0,0,GO:0051098,regulation of binding,M100,1,0
1,0,0,-2.8,0,0,GO:0002287,alpha-beta T cell activation involved in immune response,M100,1,0
1,0,0,-2.2,0,0,WP5063,FOXP3 in COVID 19,M100,1,0
0,1,0,0,-2.4,0,GO:0033673,negative regulation of kinase activity,M010,1,0
1,0,0,-2.7,0,0,GO:0061030,epithelial cell differentiation involved in mammary gland alveolus development,M100,1,0
1,0,0,-2.6,0,0,GO:0009755,hormone-mediated signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:2000136,regulation of cell proliferation involved in heart morphogenesis,M100,1,0
1,0,0,-3.3,0,0,GO:0032695,negative regulation of interleukin-12 production,M100,1,0
1,0,0,-2.2,0,0,M279,PID RB 1PATHWAY,M100,1,0
1,0,0,-2.2,0,0,hsa05133,Pertussis,M100,1,0
1,0,0,-2.1,0,0,GO:0071384,cellular response to corticosteroid stimulus,M100,1,0
0,1,0,0,-3.9,0,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M010,1,0
1,0,0,-5.8,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.8,0,0,GO:0071599,otic vesicle development,M100,1,0
1,0,0,-2.3,0,0,GO:0070498,interleukin-1-mediated signaling pathway,M100,1,0
1,0,0,-2.6,0,0,R-HSA-5655302,Signaling by FGFR1 in disease,M100,1,0
1,0,0,-7.3,0,0,R-HSA-400253,Circadian Clock,M100,1,0
1,0,0,-2,0,0,WP314,Fas ligand pathway and stress induction of heat shock proteins,M100,1,0
0,0,1,0,0,-3.8,GO:0060074,synapse maturation,M001,1,0
1,0,0,-2,0,0,GO:0001569,branching involved in blood vessel morphogenesis,M100,1,0
1,0,0,-2.2,0,0,CORUM:5193,"TNF-alpha/NF-kappa B signaling complex (CHUK, KPNA3, NFKB2, NFKBIB, REL, IKBKG,  NFKB1, NFKBIE, RELB,  NFKBIA, RELA, TNIP2)",M100,1,0
1,0,0,-4.4,0,0,WP382,MAPK signaling pathway,M100,1,0
1,0,0,-2.9,0,0,GO:0007219,Notch signaling pathway,M100,1,0
1,0,0,-5.6,0,0,WP437,EGF EGFR signaling pathway,M100,1,0
1,0,0,-9.6,0,0,GO:0048598,embryonic morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0055015,ventricular cardiac muscle cell development,M100,1,0
1,0,0,-2,0,0,GO:0010518,positive regulation of phospholipase activity,M100,1,0
0,1,0,0,-2.9,0,GO:0002576,platelet degranulation,M010,1,0
1,0,0,-2.6,0,0,GO:0001916,positive regulation of T cell mediated cytotoxicity,M100,1,0
1,0,0,-2.9,0,0,WP5331,Autophagy in pancreatic ductal adenocarcinoma,M100,1,0
1,0,0,-2,0,0,GO:0007028,cytoplasm organization,M100,1,0
1,0,0,-2.1,0,0,GO:0060444,branching involved in mammary gland duct morphogenesis,M100,1,0
1,0,0,-3.2,0,0,GO:0048332,mesoderm morphogenesis,M100,1,0
0,1,0,0,-2.6,0,GO:0060900,embryonic camera-type eye formation,M010,1,0
1,0,0,-3,0,0,GO:0032642,regulation of chemokine production,M100,1,0
1,0,0,-3.1,0,0,GO:0001656,metanephros development,M100,1,0
0,0,1,0,0,-3.5,GO:0015908,fatty acid transport,M001,1,0
0,1,0,0,-2,0,GO:0030534,adult behavior,M010,1,0
1,0,0,-2.7,0,0,GO:0051146,striated muscle cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0070528,protein kinase C signaling,M100,1,0
1,0,0,-2.2,0,0,R-HSA-111885,Opioid Signalling,M100,1,0
1,0,0,-4.1,0,0,WP4540,Hippo signaling regulation pathways,M100,1,0
1,0,0,-2.7,0,0,R-HSA-9818032,NFE2L2 regulating MDR associated enzymes,M100,1,0
1,0,0,-3.4,0,0,WP5083,Neuroinflammation and glutamatergic signaling,M100,1,0
1,0,0,-2.2,0,0,GO:0010662,regulation of striated muscle cell apoptotic process,M100,1,0
1,0,0,-3,0,0,hsa04148,Efferocytosis,M100,1,0
1,0,0,-3.9,0,0,GO:0006111,regulation of gluconeogenesis,M100,1,0
1,0,0,-6.1,0,0,GO:0048709,oligodendrocyte differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0032816,positive regulation of natural killer cell activation,M100,1,0
1,0,0,-2.3,0,0,WP734,Serotonin receptor 4 6 7 and NR3C signaling,M100,1,0
1,0,0,-2.2,0,0,GO:0002066,columnar/cuboidal epithelial cell development,M100,1,0
1,0,0,-2.8,0,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M100,1,0
1,0,0,-3.4,0,0,M88,PID CD8 TCR PATHWAY,M100,1,0
1,0,0,-5.5,0,0,GO:0060349,bone morphogenesis,M100,1,0
1,0,0,-2.8,0,0,GO:1900180,regulation of protein localization to nucleus,M100,1,0
1,0,0,-2.4,0,0,GO:0031331,positive regulation of cellular catabolic process,M100,1,0
1,0,0,-2.4,0,0,GO:0045604,regulation of epidermal cell differentiation,M100,1,0
1,0,0,-4.7,0,0,GO:0001525,angiogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:1903670,regulation of sprouting angiogenesis,M100,1,0
1,0,0,-3.7,0,0,GO:0031343,positive regulation of cell killing,M100,1,0
1,0,0,-3,0,0,R-HSA-5619507,Activation of HOX genes during differentiation,M100,1,0
1,0,0,-4,0,0,GO:0007259,receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-2.8,0,0,WP2037,Prolactin signaling pathway,M100,1,0
1,0,0,-3.4,0,0,GO:0030324,lung development,M100,1,0
1,0,0,-2.6,0,0,GO:0045778,positive regulation of ossification,M100,1,0
1,0,0,-5.3,0,0,GO:0006366,transcription by RNA polymerase II,M100,1,0
1,0,0,-2.4,0,0,GO:0002827,positive regulation of T-helper 1 type immune response,M100,1,0
1,0,0,-3,0,0,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M100,1,0
1,0,0,-2.7,0,0,GO:0032817,regulation of natural killer cell proliferation,M100,1,0
1,0,0,-2,0,0,GO:0002478,antigen processing and presentation of exogenous peptide antigen,M100,1,0
1,0,0,-5.8,0,0,hsa04625,C-type lectin receptor signaling pathway,M100,1,0
1,0,0,-3.7,0,0,GO:0038061,non-canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-2.7,0,0,GO:0050671,positive regulation of lymphocyte proliferation,M100,1,0
0,0,1,0,0,-2.7,GO:0045746,negative regulation of Notch signaling pathway,M001,1,0
1,0,0,-2.1,0,0,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M100,1,0
1,0,0,-2.2,0,0,R-HSA-8941855,RUNX3 regulates CDKN1A transcription,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9614657,FOXO-mediated transcription of cell death genes,M100,1,0
0,0,1,0,0,-3.9,GO:0045806,negative regulation of endocytosis,M001,1,0
1,0,0,-2.9,0,0,GO:0071696,ectodermal placode development,M100,1,0
1,0,0,-4.9,0,0,M115,PID REG GR PATHWAY,M100,1,0
1,0,0,-2.4,0,0,GO:1901654,response to ketone,M100,1,0
0,1,0,0,-3.3,0,WP2874,Liver X receptor pathway,M010,1,0
1,0,0,-3.7,0,0,GO:0055123,digestive system development,M100,1,0
0,1,0,0,-3.9,0,GO:1901741,positive regulation of myoblast fusion,M010,1,0
1,0,0,-3.1,0,0,WP5358,JAK STAT signaling in the regulation of Beta cells,M100,1,0
1,0,0,-2.2,0,0,R-HSA-8878171,Transcriptional regulation by RUNX1,M100,1,0
1,0,0,-2.7,0,0,GO:0060363,cranial suture morphogenesis,M100,1,0
0,1,0,0,-2.2,0,GO:1990840,response to lectin,M010,1,0
0,1,0,0,-2.4,0,WP2879,Farnesoid X receptor pathway,M010,1,0
1,0,0,-2,0,0,GO:0010575,positive regulation of vascular endothelial growth factor production,M100,1,0
1,0,0,-2.5,0,0,GO:0042102,positive regulation of T cell proliferation,M100,1,0
1,0,0,-3.3,0,0,WP5174,Ulcerative colitis signaling,M100,1,0
1,0,0,-2.5,0,0,GO:1900182,positive regulation of protein localization to nucleus,M100,1,0
1,0,0,-2,0,0,GO:0019042,viral latency,M100,1,0
1,0,0,-5.7,0,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M100,1,0
0,0,1,0,0,-2.3,GO:0032755,positive regulation of interleukin-6 production,M001,1,0
1,0,0,-2.7,0,0,GO:0045721,negative regulation of gluconeogenesis,M100,1,0
1,0,0,-4.1,0,0,GO:0070670,response to interleukin-4,M100,1,0
1,0,0,-5.1,0,0,WP75,Toll like receptor signaling pathway,M100,1,0
1,0,0,-5.3,0,0,WP5115,Network map of SARS CoV 2 signaling pathway,M100,1,0
1,0,0,-6.1,0,0,GO:0002009,morphogenesis of an epithelium,M100,1,0
0,1,0,0,-2.2,0,GO:0010743,regulation of macrophage derived foam cell differentiation,M010,1,0
1,0,0,-2.3,0,0,GO:0032956,regulation of actin cytoskeleton organization,M100,1,0
1,0,0,-4.9,0,0,GO:0042098,T cell proliferation,M100,1,0
1,0,0,-2.1,0,0,M40,PID E2F PATHWAY,M100,1,0
1,0,0,-6.7,0,0,R-HSA-168898,Toll-like Receptor Cascades,M100,1,0
1,0,0,-2.9,0,0,WP5417,Cell lineage map for neuronal differentiation,M100,1,0
1,0,0,-2,0,0,R-HSA-9818028,NFE2L2 regulates pentose phosphate pathway genes,M100,1,0
1,0,0,-4.1,0,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M100,1,0
1,0,0,-10,0,0,GO:0009792,embryo development ending in birth or egg hatching,M100,1,0
1,0,0,-3.1,0,0,R-HSA-2424491,DAP12 signaling,M100,1,0
0,0,1,0,0,-2.7,GO:0061081,positive regulation of myeloid leukocyte cytokine production involved in immune response,M001,1,0
1,0,0,-2.6,0,0,GO:2000737,negative regulation of stem cell differentiation,M100,1,0
0,1,0,0,-2.6,0,M210,PID IL8 CXCR2 PATHWAY,M010,1,0
1,0,0,-2.6,0,0,GO:2000181,negative regulation of blood vessel morphogenesis,M100,1,0
1,0,0,-2,0,0,R-HSA-445989,TAK1-dependent IKK and NF-kappa-B activation,M100,1,0
1,0,0,-9.9,0,0,GO:0035239,tube morphogenesis,M100,1,0
1,0,0,-3,0,0,GO:0042093,T-helper cell differentiation,M100,1,0
1,0,0,-7.1,0,0,GO:0032870,cellular response to hormone stimulus,M100,1,0
1,0,0,-3,0,0,GO:0014003,oligodendrocyte development,M100,1,0
1,0,0,-3.3,0,0,GO:0002076,osteoblast development,M100,1,0
1,0,0,-3.4,0,0,GO:0050921,positive regulation of chemotaxis,M100,1,0
1,0,0,-11,0,0,GO:0043009,chordate embryonic development,M100,1,0
1,0,0,-2,0,0,GO:0003176,aortic valve development,M100,1,0
1,0,0,-2,0,0,GO:0045649,regulation of macrophage differentiation,M100,1,0
1,0,0,-5.7,0,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M100,1,0
0,1,0,0,-2,0,GO:0019932,second-messenger-mediated signaling,M010,1,0
1,0,0,-4.9,0,0,WP2018,RANKL RANK signaling pathway,M100,1,0
1,0,0,-3.4,0,0,GO:0070169,positive regulation of biomineral tissue development,M100,1,0
1,0,0,-2,0,0,GO:0010458,exit from mitosis,M100,1,0
1,0,0,-5.1,0,0,GO:0060562,epithelial tube morphogenesis,M100,1,0
1,0,0,-5.5,0,0,GO:0051216,cartilage development,M100,1,0
1,0,0,-2.2,0,0,GO:0002063,chondrocyte development,M100,1,0
1,0,0,-6,0,0,GO:0007623,circadian rhythm,M100,1,0
0,1,0,0,-2.4,0,GO:0008356,asymmetric cell division,M010,1,0
1,0,0,-2.1,0,0,R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,M100,1,0
1,0,0,-2.2,0,0,R-HSA-198753,ERK/MAPK targets,M100,1,0
1,0,0,-2.2,0,0,GO:0071364,cellular response to epidermal growth factor stimulus,M100,1,0
1,0,0,-2,0,0,GO:2000105,positive regulation of DNA-templated DNA replication,M100,1,0
1,0,0,-4.7,0,0,GO:0002821,positive regulation of adaptive immune response,M100,1,0
1,0,0,-2.3,0,0,GO:0060840,artery development,M100,1,0
1,0,0,-2.1,0,0,WP3982,miRNA regulation of p53 pathway in prostate cancer,M100,1,0
0,1,0,0,-2.1,0,GO:0045061,thymic T cell selection,M010,1,0
1,0,0,-2,0,0,R-HSA-9012546,Interleukin-18 signaling,M100,1,0
1,0,0,-2.4,0,0,hsa05145,Toxoplasmosis,M100,1,0
1,0,0,-5.4,0,0,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M100,1,0
1,0,0,-3.6,0,0,GO:0061180,mammary gland epithelium development,M100,1,0
1,0,0,-2.8,0,0,WP5072,Modulators of TCR signaling and T cell activation,M100,1,0
0,1,0,0,-2.1,0,hsa04310,Wnt signaling pathway,M010,1,0
1,0,0,-3.6,0,0,GO:0071353,cellular response to interleukin-4,M100,1,0
1,0,0,-2,0,0,CORUM:6235,c-Fos-c-Jun-SAF-1 complex,M100,1,0
1,0,0,-7.1,0,0,GO:0048732,gland development,M100,1,0
1,0,0,-2.7,0,0,GO:0009629,response to gravity,M100,1,0
1,0,0,-3.2,0,0,GO:0060603,mammary gland duct morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0072164,mesonephric tubule development,M100,1,0
1,0,0,-2.6,0,0,R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,M100,1,0
1,0,0,-2.7,0,0,R-HSA-9020558,Interleukin-2 signaling,M100,1,0
1,0,0,-3.2,0,0,hsa04060,Cytokine-cytokine receptor interaction,M100,1,0
1,0,0,-2.2,0,0,M276,PID FGF PATHWAY,M100,1,0
1,0,0,-2.5,0,0,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M100,1,0
1,0,0,-4,0,0,GO:0048617,embryonic foregut morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0032869,cellular response to insulin stimulus,M100,1,0
1,0,0,-2.2,0,0,GO:0002889,regulation of immunoglobulin mediated immune response,M100,1,0
1,0,0,-2.3,0,0,GO:0043584,nose development,M100,1,0
1,0,0,-2.6,0,0,GO:0051145,smooth muscle cell differentiation,M100,1,0
1,0,0,-2,0,0,GO:0006089,lactate metabolic process,M100,1,0
1,0,0,-6.4,0,0,GO:0048511,rhythmic process,M100,1,0
0,1,0,0,-2.1,0,GO:0097028,dendritic cell differentiation,M010,1,0
1,0,0,-2,0,0,CORUM:1521,p300-SMAD1-STAT3 complex,M100,1,0
1,0,0,-3.3,0,0,GO:0021700,developmental maturation,M100,1,0
1,0,0,-2.2,0,0,WP5272,LDL influence on CD14 and TLR4,M100,1,0
0,1,0,0,-3.9,0,R-HSA-6798695,Neutrophil degranulation,M010,1,0
0,1,0,0,-2.6,0,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M010,1,0
1,0,0,-3.6,0,0,hsa04915,Estrogen signaling pathway,M100,1,0
1,0,0,-3.3,0,0,GO:0001708,cell fate specification,M100,1,0
1,0,0,-4.5,0,0,WP4482,Vitamin D in inflammatory diseases,M100,1,0
1,0,0,-2.9,0,0,M94,PID FAS PATHWAY,M100,1,0
1,0,0,-4.5,0,0,GO:0061061,muscle structure development,M100,1,0
1,0,0,-2,0,0,GO:0060326,cell chemotaxis,M100,1,0
1,0,0,-2.4,0,0,GO:0045581,negative regulation of T cell differentiation,M100,1,0
1,0,0,-2.7,0,0,hsa04145,Phagosome,M100,1,0
1,0,0,-3.6,0,0,GO:1904035,regulation of epithelial cell apoptotic process,M100,1,0
0,1,0,0,-2,0,M5493,WNT SIGNALING,M010,1,0
1,0,0,-5.2,0,0,GO:0071383,cellular response to steroid hormone stimulus,M100,1,0
0,1,0,0,-2.5,0,hsa04613,Neutrophil extracellular trap formation,M010,1,0
0,1,0,0,-2.1,0,M206,PID PDGFRA PATHWAY,M010,1,0
1,0,0,-2.1,0,0,R-HSA-198693,AKT phosphorylates targets in the nucleus,M100,1,0
0,1,0,0,-2.1,0,GO:0017145,stem cell division,M010,1,0
1,0,0,-2.6,0,0,GO:0060416,response to growth hormone,M100,1,0
1,0,0,-3,0,0,GO:0060485,mesenchyme development,M100,1,0
1,0,0,-4.8,0,0,hsa04935,"Growth hormone synthesis, secretion and action",M100,1,0
1,0,0,-2.4,0,0,GO:0045682,regulation of epidermis development,M100,1,0
1,0,0,-3.3,0,0,R-HSA-913531,Interferon Signaling,M100,1,0
1,0,0,-2,0,0,GO:0045626,negative regulation of T-helper 1 cell differentiation,M100,1,0
1,0,0,-2.9,0,0,WP581,EPO receptor signaling,M100,1,0
1,0,0,-2,0,0,WP4874,CAMKK2 pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0045740,positive regulation of DNA replication,M100,1,0
0,1,0,0,-2.8,0,WP4719,Eicosanoid metabolism via cyclooxygenases COX,M010,1,0
1,0,0,-2.9,0,0,GO:0046643,regulation of gamma-delta T cell activation,M100,1,0
0,1,0,0,-2.1,0,GO:0045628,regulation of T-helper 2 cell differentiation,M010,1,0
1,0,0,-3.9,0,0,R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",M100,1,0
1,0,0,-2.7,0,0,GO:2000179,positive regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2.6,0,0,GO:0050792,regulation of viral process,M100,1,0
1,0,0,-3,0,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M100,1,0
1,0,0,-2,0,0,R-HSA-381771,"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",M100,1,0
1,0,0,-4.3,0,0,hsa04919,Thyroid hormone signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0006469,negative regulation of protein kinase activity,M010,1,0
1,0,0,-3.5,0,0,GO:0045667,regulation of osteoblast differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0051607,defense response to virus,M100,1,0
1,0,0,-3.1,0,0,GO:0031667,response to nutrient levels,M100,1,0
1,0,0,-2.7,0,0,GO:0090335,regulation of brown fat cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0007159,leukocyte cell-cell adhesion,M100,1,0
0,1,0,0,-2,0,GO:0034113,heterotypic cell-cell adhesion,M010,1,0
0,1,0,0,-2,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M010,1,0
1,0,0,-2.1,0,0,hsa04961,Endocrine and other factor-regulated calcium reabsorption,M100,1,0
0,0,1,0,0,-2.6,GO:0090407,organophosphate biosynthetic process,M001,1,0
1,0,0,-2.1,0,0,GO:1904950,negative regulation of establishment of protein localization,M100,1,0
1,0,0,-2.7,0,0,GO:0031960,response to corticosteroid,M100,1,0
1,0,0,-4.3,0,0,GO:0007405,neuroblast proliferation,M100,1,0
1,0,0,-4.5,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M100,1,0
0,1,0,0,-2.2,0,WP1992,Genes targeted by miRNAs in adipocytes,M010,1,0
1,0,0,-2.2,0,0,R-HSA-2559585,Oncogene Induced Senescence,M100,1,0
1,0,0,-2.6,0,0,WP4949,16p11 2 proximal deletion syndrome,M100,1,0
1,0,0,-2.2,0,0,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,M100,1,0
1,0,0,-2,0,0,GO:0060718,chorionic trophoblast cell differentiation,M100,1,0
1,0,0,-3.5,0,0,WP3651,Pathways affected in adenoid cystic carcinoma,M100,1,0
0,1,0,0,-2.4,0,WP5321,Prostaglandin and leukotriene metabolism in senescence,M010,1,0
0,0,1,0,0,-2.2,GO:0046486,glycerolipid metabolic process,M001,1,0
1,0,0,-2.5,0,0,hsa05170,Human immunodeficiency virus 1 infection,M100,1,0
1,0,0,-2.5,0,0,R-HSA-9013148,CDC42 GTPase cycle,M100,1,0
1,0,0,-2.1,0,0,GO:0060675,ureteric bud morphogenesis,M100,1,0
1,0,0,-2.9,0,0,GO:0045332,phospholipid translocation,M100,1,0
0,1,0,0,-2.2,0,GO:0051642,centrosome localization,M010,1,0
0,0,1,0,0,-2.3,GO:0098659,inorganic cation import across plasma membrane,M001,1,0
1,0,0,-5.8,0,0,GO:0048706,embryonic skeletal system development,M100,1,0
0,1,0,0,-2.2,0,GO:0070663,regulation of leukocyte proliferation,M010,1,0
1,0,0,-2.7,0,0,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-2.7,0,0,GO:0060333,type II interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:1902930,regulation of alcohol biosynthetic process,M100,1,0
1,0,0,-4,0,0,GO:0060350,endochondral bone morphogenesis,M100,1,0
1,0,0,-3.4,0,0,WP49,IL 2 signaling pathway,M100,1,0
1,0,0,-6,0,0,GO:0060348,bone development,M100,1,0
1,0,0,-8.9,0,0,GO:0001701,in utero embryonic development,M100,1,0
1,0,0,-5,0,0,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M100,1,0
0,1,0,0,-2.3,0,GO:0030890,positive regulation of B cell proliferation,M010,1,0
0,1,0,0,-2.6,0,hsa00590,Arachidonic acid metabolism,M010,1,0
1,0,0,-3.4,0,0,GO:0071347,cellular response to interleukin-1,M100,1,0
1,0,0,-6.6,0,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M100,1,0
0,1,0,0,-2.4,0,R-HSA-76009,Platelet Aggregation (Plug Formation),M010,1,0
1,0,0,-4,0,0,R-HSA-400206,Regulation of lipid metabolism by PPARalpha,M100,1,0
1,0,0,-2.1,0,0,GO:1902932,positive regulation of alcohol biosynthetic process,M100,1,0
1,0,0,-3.3,0,0,GO:1905155,positive regulation of membrane invagination,M100,1,0
1,0,0,-2.4,0,0,GO:2000352,negative regulation of endothelial cell apoptotic process,M100,1,0
1,0,0,-2.6,0,0,GO:0002292,T cell differentiation involved in immune response,M100,1,0
1,0,0,-2.1,0,0,R-HSA-3700989,Transcriptional Regulation by TP53,M100,1,0
0,1,0,0,-2.9,0,WP3,Transcriptional activation by NRF2 in response to phytochemicals,M010,1,0
1,0,0,-5.8,0,0,GO:0061138,morphogenesis of a branching epithelium,M100,1,0
0,1,0,0,-3.7,0,R-HSA-9664407,Parasite infection,M010,1,0
0,1,0,0,-2.2,0,GO:0050670,regulation of lymphocyte proliferation,M010,1,0
1,0,0,-2.6,0,0,GO:0044088,regulation of vacuole organization,M100,1,0
1,0,0,-4,0,0,GO:0030522,intracellular receptor signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0002826,negative regulation of T-helper 1 type immune response,M100,1,0
1,0,0,-5.3,0,0,hsa05207,Chemical carcinogenesis - receptor activation,M100,1,0
1,0,0,-2,0,0,GO:0040014,regulation of multicellular organism growth,M100,1,0
1,0,0,-3.3,0,0,R-HSA-9671555,Signaling by PDGFR in disease,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M100,1,0
0,1,0,0,-3,0,GO:0030888,regulation of B cell proliferation,M010,1,0
1,0,0,-3.4,0,0,R-HSA-199920,CREB phosphorylation,M100,1,0
0,1,0,0,-2.7,0,GO:0061245,establishment or maintenance of bipolar cell polarity,M010,1,0
1,0,0,-2.2,0,0,GO:0007265,Ras protein signal transduction,M100,1,0
1,0,0,-2,0,0,GO:2000110,negative regulation of macrophage apoptotic process,M100,1,0
1,0,0,-2.1,0,0,M234,PID IL2 STAT5 PATHWAY,M100,1,0
1,0,0,-2.4,0,0,M288,PID HES HEY PATHWAY,M100,1,0
0,0,1,0,0,-2.8,R-HSA-425407,SLC-mediated transmembrane transport,M001,1,0
1,0,0,-2,0,0,GO:0071385,cellular response to glucocorticoid stimulus,M100,1,0
1,0,0,-5.6,0,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.7,0,0,GO:1901862,negative regulation of muscle tissue development,M100,1,0
1,0,0,-5,0,0,GO:0072089,stem cell proliferation,M100,1,0
1,0,0,-5.5,0,0,hsa04620,Toll-like receptor signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0010664,negative regulation of striated muscle cell apoptotic process,M100,1,0
1,0,0,-2.9,0,0,GO:0008366,axon ensheathment,M100,1,0
1,0,0,-4.1,0,0,R-HSA-8878166,Transcriptional regulation by RUNX2,M100,1,0
1,0,0,-3.7,0,0,GO:0002687,positive regulation of leukocyte migration,M100,1,0
1,0,0,-3.8,0,0,WP2853,Endoderm differentiation,M100,1,0
1,0,0,-6.2,0,0,GO:0030879,mammary gland development,M100,1,0
1,0,0,-2,0,0,GO:0071352,cellular response to interleukin-2,M100,1,0
0,1,0,0,-2.4,0,GO:0071241,cellular response to inorganic substance,M010,1,0
1,0,0,-2.7,0,0,GO:0043313,regulation of neutrophil degranulation,M100,1,0
0,1,0,0,-2.1,0,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M010,1,0
1,0,0,-2.6,0,0,GO:0051147,regulation of muscle cell differentiation,M100,1,0
1,0,0,-2.9,0,0,GO:0051961,negative regulation of nervous system development,M100,1,0
1,0,0,-2.1,0,0,GO:0046532,regulation of photoreceptor cell differentiation,M100,1,0
1,0,0,-2.6,0,0,M145,PID P53 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:0009648,photoperiodism,M100,1,0
1,0,0,-3.3,0,0,GO:0090336,positive regulation of brown fat cell differentiation,M100,1,0
1,0,0,-3.2,0,0,R-HSA-2172127,DAP12 interactions,M100,1,0
1,0,0,-5.2,0,0,WP3888,VEGFA VEGFR2 signaling,M100,1,0
1,0,0,-4.5,0,0,WP3599,Transcription factor regulation in adipogenesis,M100,1,0
1,0,0,-2,0,0,WP722,Serotonin HTR1 group and FOS pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0016447,somatic recombination of immunoglobulin gene segments,M100,1,0
1,0,0,-2.7,0,0,GO:0021546,rhombomere development,M100,1,0
1,0,0,-2.1,0,0,hsa04371,Apelin signaling pathway,M100,1,0
1,0,0,-6.6,0,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M100,1,0
0,1,0,0,-3.9,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M010,1,0
0,1,0,0,-2.1,0,GO:0036336,dendritic cell migration,M010,1,0
0,1,0,0,-2,0,GO:0150077,regulation of neuroinflammatory response,M010,1,0
1,0,0,-3.1,0,0,WP4871,Kisspeptin kisspeptin receptor system in the ovary,M100,1,0
1,0,0,-2.2,0,0,GO:0002719,negative regulation of cytokine production involved in immune response,M100,1,0
1,0,0,-3.4,0,0,R-HSA-8939902,Regulation of RUNX2 expression and activity,M100,1,0
1,0,0,-5.9,0,0,GO:0001892,embryonic placenta development,M100,1,0
1,0,0,-3,0,0,GO:0051384,response to glucocorticoid,M100,1,0
1,0,0,-2.1,0,0,R-HSA-8953750,Transcriptional Regulation by E2F6,M100,1,0
1,0,0,-2.3,0,0,GO:0042752,regulation of circadian rhythm,M100,1,0
0,0,1,0,0,-2.7,GO:0010876,lipid localization,M001,1,0
1,0,0,-3.5,0,0,GO:0002052,positive regulation of neuroblast proliferation,M100,1,0
1,0,0,-2.1,0,0,WP4263,Pancreatic adenocarcinoma pathway,M100,1,0
1,0,0,-5.7,0,0,GO:0007389,pattern specification process,M100,1,0
1,0,0,-2.1,0,0,GO:0001823,mesonephros development,M100,1,0
0,1,0,0,-3,0,GO:0051651,maintenance of location in cell,M010,1,0
1,0,0,-2.7,0,0,WP5224,2q37 copy number variation syndrome,M100,1,0
0,0,1,0,0,-2,hsa04666,Fc gamma R-mediated phagocytosis,M001,1,0
0,1,0,0,-2.4,0,GO:0044770,cell cycle phase transition,M010,1,0
1,0,0,-2.9,0,0,GO:0051054,positive regulation of DNA metabolic process,M100,1,0
1,0,0,-2.1,0,0,GO:0007622,rhythmic behavior,M100,1,0
0,1,0,0,-2,0,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M010,1,0
1,0,0,-2.4,0,0,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M100,1,0
1,0,0,-5.2,0,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.2,0,0,R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0002712,regulation of B cell mediated immunity,M100,1,0
1,0,0,-2.2,0,0,R-HSA-749476,RNA Polymerase III Abortive And Retractive Initiation,M100,1,0
1,0,0,-3.3,0,0,GO:0071697,ectodermal placode morphogenesis,M100,1,0
1,0,0,-3.4,0,0,GO:0032819,positive regulation of natural killer cell proliferation,M100,1,0
1,0,0,-3.1,0,0,WP5074,Kallmann syndrome,M100,1,0
1,0,0,-2.8,0,0,WP2203,Thymic stromal lymphopoietin TSLP signaling pathway,M100,1,0
1,0,0,-3.4,0,0,R-HSA-9700206,Signaling by ALK in cancer,M100,1,0
1,0,0,-6.5,0,0,GO:0048704,embryonic skeletal system morphogenesis,M100,1,0
1,0,0,-5.4,0,0,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M100,1,0
0,1,0,0,-2.6,0,GO:0019369,arachidonic acid metabolic process,M010,1,0
1,0,0,-2,0,0,GO:0014009,glial cell proliferation,M100,1,0
1,0,0,-3.9,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-3,0,0,GO:0048546,digestive tract morphogenesis,M100,1,0
1,0,0,-3,0,0,GO:0042552,myelination,M100,1,0
0,1,0,0,-3.5,0,GO:0001562,response to protozoan,M010,1,0
1,0,0,-2.1,0,0,GO:2000739,regulation of mesenchymal stem cell differentiation,M100,1,0
0,1,0,0,-2.6,0,GO:0043302,positive regulation of leukocyte degranulation,M010,1,0
1,0,0,-2.2,0,0,GO:0090183,regulation of kidney development,M100,1,0
1,0,0,-4,0,0,GO:0050729,positive regulation of inflammatory response,M100,1,0
1,0,0,-3.4,0,0,hsa05140,Leishmaniasis,M100,1,0
1,0,0,-2.2,0,0,GO:0048844,artery morphogenesis,M100,1,0
0,0,1,0,0,-2.6,GO:0043368,positive T cell selection,M001,1,0
1,0,0,-2.8,0,0,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-3.2,0,0,hsa04920,Adipocytokine signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0048608,reproductive structure development,M100,1,0
1,0,0,-2.2,0,0,R-HSA-74158,RNA Polymerase III Transcription,M100,1,0
1,0,0,-2,0,0,GO:0006900,vesicle budding from membrane,M100,1,0
1,0,0,-3.9,0,0,GO:0034612,response to tumor necrosis factor,M100,1,0
1,0,0,-3.2,0,0,hsa05323,Rheumatoid arthritis,M100,1,0
1,0,0,-4,0,0,GO:0003151,outflow tract morphogenesis,M100,1,0
1,0,0,-2,0,0,R-HSA-8941284,RUNX2 regulates chondrocyte maturation,M100,1,0
1,0,0,-4,0,0,GO:0097696,receptor signaling pathway via STAT,M100,1,0
1,0,0,-7.5,0,0,WP2857,Mesodermal commitment pathway,M100,1,0
1,0,0,-2.2,0,0,WP4655,Cytosolic DNA sensing pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M010,1,0
0,1,0,0,-2,0,GO:0042100,B cell proliferation,M010,1,0
1,0,0,-3.4,0,0,GO:0010906,regulation of glucose metabolic process,M100,1,0
1,0,0,-2,0,0,GO:0030593,neutrophil chemotaxis,M100,1,0
1,0,0,-3.1,0,0,GO:0097035,regulation of membrane lipid distribution,M100,1,0
1,0,0,-3.3,0,0,GO:0021780,glial cell fate specification,M100,1,0
1,0,0,-3.9,0,0,GO:0071772,response to BMP,M100,1,0
1,0,0,-2.6,0,0,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M100,1,0
1,0,0,-2.4,0,0,hsa05225,Hepatocellular carcinoma,M100,1,0
1,0,0,-2.1,0,0,WP2328,Allograft rejection,M100,1,0
0,1,0,0,-2.1,0,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M010,1,0
1,0,0,-4.1,0,0,R-HSA-1989781,PPARA activates gene expression,M100,1,0
0,0,1,0,0,-3.2,GO:0045017,glycerolipid biosynthetic process,M001,1,0
1,0,0,-4.4,0,0,GO:0007498,mesoderm development,M100,1,0
0,0,1,0,0,-2.3,GO:0006820,monoatomic anion transport,M001,1,0
1,0,0,-2.7,0,0,R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,M100,1,0
1,0,0,-2.2,0,0,WP3414,Initiation of transcription and translation elongation at the HIV 1 LTR,M100,1,0
1,0,0,-2,0,0,R-HSA-6811555,PI5P Regulates TP53 Acetylation,M100,1,0
1,0,0,-5.1,0,0,WP2324,AGE RAGE pathway,M100,1,0
1,0,0,-2.7,0,0,GO:1905064,negative regulation of vascular associated smooth muscle cell differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:0044089,positive regulation of cellular component biogenesis,M100,1,0
1,0,0,-4,0,0,GO:0035107,appendage morphogenesis,M100,1,0
1,0,0,-4.4,0,0,R-HSA-450294,MAP kinase activation,M100,1,0
1,0,0,-2.6,0,0,M8626,SIG BCR SIGNALING PATHWAY,M100,1,0
1,0,0,-4.3,0,0,GO:0006959,humoral immune response,M100,1,0
0,1,0,0,-2.4,0,GO:0097581,lamellipodium organization,M010,1,0
0,0,1,0,0,-2.2,GO:0051092,positive regulation of NF-kappaB transcription factor activity,M001,1,0
0,1,0,0,-3.2,0,GO:0002886,regulation of myeloid leukocyte mediated immunity,M010,1,0
1,0,0,-2.2,0,0,WP5348,11p11 2 copy number variation syndrome,M100,1,0
1,0,0,-5.7,0,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M100,1,0
1,0,0,-2.8,0,0,GO:0007249,canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-2.1,0,0,GO:0009649,entrainment of circadian clock,M100,1,0
0,1,0,0,-2.3,0,GO:0030900,forebrain development,M010,1,0
1,0,0,-4.6,0,0,GO:0060443,mammary gland morphogenesis,M100,1,0
1,0,0,-5.9,0,0,GO:0001763,morphogenesis of a branching structure,M100,1,0
1,0,0,-2.2,0,0,GO:0021772,olfactory bulb development,M100,1,0
1,0,0,-3.1,0,0,GO:0060173,limb development,M100,1,0
1,0,0,-4.4,0,0,GO:0001890,placenta development,M100,1,0
1,0,0,-3.9,0,0,GO:0042475,odontogenesis of dentin-containing tooth,M100,1,0
1,0,0,-2.1,0,0,GO:0021529,spinal cord oligodendrocyte cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0021988,olfactory lobe development,M100,1,0
1,0,0,-6.1,0,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M100,1,0
0,1,0,0,-2.4,0,GO:0030168,platelet activation,M010,1,0
1,0,0,-2.1,0,0,GO:0018105,peptidyl-serine phosphorylation,M100,1,0
0,0,1,0,0,-2.1,GO:0015850,organic hydroxy compound transport,M001,1,0
1,0,0,-2.1,0,0,GO:2000109,regulation of macrophage apoptotic process,M100,1,0
1,0,0,-4.6,0,0,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,M100,1,0
1,0,0,-2,0,0,GO:1905521,regulation of macrophage migration,M100,1,0
1,0,0,-2.9,0,0,WP3858,Toll like receptor signaling related to MyD88,M100,1,0
1,0,0,-2.2,0,0,GO:0070672,response to interleukin-15,M100,1,0
1,0,0,-3.9,0,0,hsa05206,MicroRNAs in cancer,M100,1,0
1,0,0,-2,0,0,WP289,Myometrial relaxation and contraction pathways,M100,1,0
1,0,0,-2.1,0,0,GO:0042492,gamma-delta T cell differentiation,M100,1,0
0,0,1,0,0,-3.1,GO:0006690,icosanoid metabolic process,M001,1,0
0,1,0,0,-2,0,hsa04750,Inflammatory mediator regulation of TRP channels,M010,1,0
1,0,0,-3.9,0,0,M113,PID NFAT 3PATHWAY,M100,1,0
1,0,0,-3,0,0,GO:0010718,positive regulation of epithelial to mesenchymal transition,M100,1,0
0,1,0,0,-2.8,0,GO:1903305,regulation of regulated secretory pathway,M010,1,0
0,1,0,0,-2.4,0,GO:1900407,regulation of cellular response to oxidative stress,M010,1,0
1,0,0,-2,0,0,GO:0043525,positive regulation of neuron apoptotic process,M100,1,0
1,0,0,-2.3,0,0,GO:0046885,regulation of hormone biosynthetic process,M100,1,0
1,0,0,-3.3,0,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-3.3,0,0,WP4481,Resistin as a regulator of inflammation,M100,1,0
1,0,0,-3.8,0,0,WP2431,Spinal cord injury,M100,1,0
1,0,0,-3.3,0,0,R-HSA-8983432,Interleukin-15 signaling,M100,1,0
1,0,0,-3.6,0,0,R-HSA-1280218,Adaptive Immune System,M100,1,0
1,0,0,-2.8,0,0,GO:0048015,phosphatidylinositol-mediated signaling,M100,1,0
1,0,0,-3.6,0,0,GO:0040007,growth,M100,1,0
1,0,0,-4.3,0,0,GO:0006109,regulation of carbohydrate metabolic process,M100,1,0
1,0,0,-2.2,0,0,GO:0061333,renal tubule morphogenesis,M100,1,0
1,0,0,-2.5,0,0,WP4880,Host pathogen interaction of human coronaviruses interferon induction,M100,1,0
0,1,0,0,-3.6,0,GO:0050869,negative regulation of B cell activation,M010,1,0
1,0,0,-13,0,0,GO:0048568,embryonic organ development,M100,1,0
0,1,0,0,-2.6,0,R-HSA-76002,"Platelet activation, signaling and aggregation",M010,1,0
1,0,0,-3.2,0,0,GO:0030509,BMP signaling pathway,M100,1,0
0,0,1,0,0,-2.8,GO:0006869,lipid transport,M001,1,0
1,0,0,-8.9,0,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M100,1,0
1,0,0,-2.6,0,0,GO:0030851,granulocyte differentiation,M100,1,0
0,1,0,0,-2.9,0,M99,PID TXA2PATHWAY,M010,1,0
1,0,0,-2.9,0,0,M241,PID RAC1 REG PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0007595,lactation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-8853884,Transcriptional Regulation by VENTX,M100,1,0
1,0,0,-2.2,0,0,GO:0032940,secretion by cell,M100,1,0
1,0,0,-2.5,0,0,GO:0032651,regulation of interleukin-1 beta production,M100,1,0
1,0,0,-3.9,0,0,WP5293,Acute myeloid leukemia,M100,1,0
1,0,0,-2.4,0,0,hsa04710,Circadian rhythm,M100,1,0
0,1,0,0,-2,0,GO:0044772,mitotic cell cycle phase transition,M010,1,0
1,0,0,-2,0,0,GO:0061072,iris morphogenesis,M100,1,0
0,1,0,0,-2.6,0,GO:0043299,leukocyte degranulation,M010,1,0
1,0,0,-2.4,0,0,GO:0043153,entrainment of circadian clock by photoperiod,M100,1,0
1,0,0,-5.1,0,0,WP127,IL 5 signaling pathway,M100,1,0
0,1,0,0,-2,0,GO:0032660,regulation of interleukin-17 production,M010,1,0
1,0,0,-6.3,0,0,GO:0048514,blood vessel morphogenesis,M100,1,0
1,0,0,-3.9,0,0,WP4808,Endochondral ossification with skeletal dysplasias,M100,1,0
1,0,0,-3.9,0,0,WP474,Endochondral ossification,M100,1,0
1,0,0,-2.6,0,0,GO:0023019,signal transduction involved in regulation of gene expression,M100,1,0
1,0,0,-2.3,0,0,GO:0002726,positive regulation of T cell cytokine production,M100,1,0
1,0,0,-5.4,0,0,hsa04218,Cellular senescence,M100,1,0
1,0,0,-2.2,0,0,R-HSA-2142753,Arachidonic acid metabolism,M100,1,0
1,0,0,-2.2,0,0,GO:0003264,regulation of cardioblast proliferation,M100,1,0
1,0,0,-2.8,0,0,hsa04912,GnRH signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:0006826,iron ion transport,M100,1,0
0,1,0,0,-2.8,0,GO:0098657,import into cell,M010,1,0
1,0,0,-4.2,0,0,GO:0060795,cell fate commitment involved in formation of primary germ layer,M100,1,0
0,1,0,0,-2.4,0,GO:0042060,wound healing,M010,1,0
1,0,0,-3.9,0,0,R-HSA-9607240,FLT3 Signaling,M100,1,0
1,0,0,-5.2,0,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M100,1,0
0,1,0,0,-2.2,0,GO:0042742,defense response to bacterium,M010,1,0
0,1,0,0,-2.3,0,GO:0010563,negative regulation of phosphorus metabolic process,M010,1,0
1,0,0,-2.6,0,0,WP4155,Endometrial cancer,M100,1,0
1,0,0,-3.6,0,0,GO:0060021,roof of mouth development,M100,1,0
1,0,0,-2.1,0,0,GO:0016202,regulation of striated muscle tissue development,M100,1,0
0,1,0,0,-5.1,0,hsa04611,Platelet activation,M010,1,0
1,0,0,-2.6,0,0,GO:0034204,lipid translocation,M100,1,0
1,0,0,-2.5,0,0,M166,PID ATF2 PATHWAY,M100,1,0
1,0,0,-2.6,0,0,WP2011,SREBF and miR33 in cholesterol and lipid homeostasis,M100,1,0
0,1,0,0,-2.8,0,GO:0032507,maintenance of protein location in cell,M010,1,0
1,0,0,-8.9,0,0,GO:0071396,cellular response to lipid,M100,1,0
1,0,0,-2.8,0,0,GO:0002704,negative regulation of leukocyte mediated immunity,M100,1,0
1,0,0,-2.7,0,0,GO:0048340,paraxial mesoderm morphogenesis,M100,1,0
0,1,0,0,-2.8,0,GO:0070306,lens fiber cell differentiation,M010,1,0
0,1,0,0,-2,0,hsa04061,Viral protein interaction with cytokine and cytokine receptor,M010,1,0
1,0,0,-2.4,0,0,WP2112,IL 17 signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0048736,appendage development,M100,1,0
1,0,0,-2.8,0,0,GO:2000401,regulation of lymphocyte migration,M100,1,0
1,0,0,-6.5,0,0,R-HSA-9679191,Potential therapeutics for SARS,M100,1,0
1,0,0,-2,0,0,CORUM:1827,PML-SMAD2/3-SARA complex,M100,1,0
1,0,0,-2.1,0,0,GO:0045599,negative regulation of fat cell differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:0038113,interleukin-9-mediated signaling pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0042326,negative regulation of phosphorylation,M010,1,0
1,0,0,-3.5,0,0,GO:0002706,regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-4.4,0,0,GO:0002698,negative regulation of immune effector process,M100,1,0
1,0,0,-7.1,0,0,GO:0009725,response to hormone,M100,1,0
1,0,0,-2.7,0,0,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M100,1,0
0,1,0,0,-2.6,0,GO:0060143,positive regulation of syncytium formation by plasma membrane fusion,M010,1,0
1,0,0,-3.4,0,0,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M100,1,0
1,0,0,-3.4,0,0,GO:0045600,positive regulation of fat cell differentiation,M100,1,0
1,0,0,-2.4,0,0,GO:0002224,toll-like receptor signaling pathway,M100,1,0
1,0,0,-8.2,0,0,M2,PID SMAD2 3NUCLEAR PATHWAY,M100,1,0
1,0,0,-4.2,0,0,hsa05164,Influenza A,M100,1,0
1,0,0,-2.1,0,0,GO:0032808,lacrimal gland development,M100,1,0
1,0,0,-3,0,0,GO:0030225,macrophage differentiation,M100,1,0
1,0,0,-5.7,0,0,GO:2000629,negative regulation of miRNA metabolic process,M100,1,0
1,0,0,-3.8,0,0,GO:1902692,regulation of neuroblast proliferation,M100,1,0
1,0,0,-2.8,0,0,GO:0097094,craniofacial suture morphogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0070301,cellular response to hydrogen peroxide,M100,1,0
1,0,0,-5.4,0,0,GO:0007162,negative regulation of cell adhesion,M100,1,0
1,0,0,-2.3,0,0,GO:0001657,ureteric bud development,M100,1,0
0,0,1,0,0,-2.1,GO:0007611,learning or memory,M001,1,0
1,0,0,-2.6,0,0,GO:0009299,mRNA transcription,M100,1,0
0,1,0,0,-2,0,GO:0002831,regulation of response to biotic stimulus,M010,1,0
1,0,0,-3.1,0,0,GO:0043010,camera-type eye development,M100,1,0
1,0,0,-2.8,0,0,GO:0001710,mesodermal cell fate commitment,M100,1,0
1,0,0,-4.1,0,0,hsa05215,Prostate cancer,M100,1,0
1,0,0,-3.1,0,0,GO:0035137,hindlimb morphogenesis,M100,1,0
1,0,0,-4,0,0,GO:0060541,respiratory system development,M100,1,0
1,0,0,-2.3,0,0,R-HSA-1257604,PIP3 activates AKT signaling,M100,1,0
1,0,0,-2.4,0,0,GO:0070849,response to epidermal growth factor,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,M100,1,0
0,0,1,0,0,-2.3,GO:0006644,phospholipid metabolic process,M001,1,0
1,0,0,-5.4,0,0,GO:0007423,sensory organ development,M100,1,0
1,0,0,-2.2,0,0,GO:0045616,regulation of keratinocyte differentiation,M100,1,0
0,1,0,0,-3.4,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M010,1,0
1,0,0,-2.1,0,0,R-HSA-3656532,TGFBR1 KD Mutants in Cancer,M100,1,0
1,0,0,-2.4,0,0,GO:0007015,actin filament organization,M100,1,0
1,0,0,-6.2,0,0,GO:0048729,tissue morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:0062013,positive regulation of small molecule metabolic process,M100,1,0
1,0,0,-4.1,0,0,GO:0030500,regulation of bone mineralization,M100,1,0
0,1,0,0,-3.9,0,GO:0043300,regulation of leukocyte degranulation,M010,1,0
1,0,0,-3.4,0,0,GO:0035115,embryonic forelimb morphogenesis,M100,1,0
1,0,0,-3.9,0,0,GO:0071773,cellular response to BMP stimulus,M100,1,0
1,0,0,-2.5,0,0,R-HSA-9006936,Signaling by TGFB family members,M100,1,0
1,0,0,-2,0,0,R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,M100,1,0
1,0,0,-2.1,0,0,GO:0071281,cellular response to iron ion,M100,1,0
1,0,0,-5,0,0,GO:1901342,regulation of vasculature development,M100,1,0
1,0,0,-2.9,0,0,GO:0048333,mesodermal cell differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:0002053,positive regulation of mesenchymal cell proliferation,M100,1,0
1,0,0,-3.7,0,0,GO:1901655,cellular response to ketone,M100,1,0
1,0,0,-2.4,0,0,GO:1904892,regulation of receptor signaling pathway via STAT,M100,1,0
0,1,0,0,-2.2,0,GO:1903307,positive regulation of regulated secretory pathway,M010,1,0
1,0,0,-2.2,0,0,GO:0030316,osteoclast differentiation,M100,1,0
1,0,0,-3,0,0,M200,PID ERA GENOMIC PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:1904263,positive regulation of TORC1 signaling,M100,1,0
1,0,0,-2.1,0,0,WP516,Hypertrophy model,M100,1,0
1,0,0,-2.2,0,0,GO:0003197,endocardial cushion development,M100,1,0
1,0,0,-3.3,0,0,WP22,IL 9 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0060337,type I interferon-mediated signaling pathway,M100,1,0
0,1,0,0,-3,0,GO:0060392,negative regulation of SMAD protein signal transduction,M010,1,0
1,0,0,-2.1,0,0,GO:0048634,regulation of muscle organ development,M100,1,0
1,0,0,-2.3,0,0,GO:0042789,mRNA transcription by RNA polymerase II,M100,1,0
1,0,0,-2.7,0,0,GO:0035589,G protein-coupled purinergic nucleotide receptor signaling pathway,M100,1,0
1,0,0,-3.4,0,0,GO:0006468,protein phosphorylation,M100,1,0
1,0,0,-2.2,0,0,GO:0071230,cellular response to amino acid stimulus,M100,1,0
1,0,0,-6.4,0,0,GO:0022612,gland morphogenesis,M100,1,0
0,1,0,0,-2.7,0,GO:0035088,establishment or maintenance of apical/basal cell polarity,M010,1,0
1,0,0,-2.7,0,0,R-HSA-5607763,CLEC7A (Dectin-1) induces NFAT activation,M100,1,0
1,0,0,-2.4,0,0,GO:2000772,regulation of cellular senescence,M100,1,0
0,1,0,0,-2.6,0,GO:0051282,regulation of sequestering of calcium ion,M010,1,0
1,0,0,-3.4,0,0,R-HSA-8939211,ESR-mediated signaling,M100,1,0
0,1,0,0,-2.4,0,R-HSA-9013423,RAC3 GTPase cycle,M010,1,0
0,1,0,0,-3.2,0,GO:0002532,production of molecular mediator involved in inflammatory response,M010,1,0
0,1,0,0,-2.2,0,GO:0002467,germinal center formation,M010,1,0
1,0,0,-4.2,0,0,WP585,Interferon type I signaling pathways,M100,1,0
1,0,0,-3.1,0,0,GO:0010565,regulation of cellular ketone metabolic process,M100,1,0
1,0,0,-2.5,0,0,WP2036,TNF related weak inducer of apoptosis TWEAK signaling pathway,M100,1,0
1,0,0,-3.6,0,0,R-HSA-9674555,Signaling by CSF3 (G-CSF),M100,1,0
1,0,0,-2.2,0,0,R-HSA-4420097,VEGFA-VEGFR2 Pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0010039,response to iron ion,M100,1,0
1,0,0,-6,0,0,R-HSA-166166,MyD88-independent TLR4 cascade,M100,1,0
1,0,0,-2.5,0,0,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M100,1,0
1,0,0,-6,0,0,GO:0006351,DNA-templated transcription,M100,1,0
1,0,0,-3.5,0,0,WP4255,Non small cell lung cancer,M100,1,0
1,0,0,-3.2,0,0,WP4559,Interactions between immune cells and microRNAs in tumor microenvironment,M100,1,0
1,0,0,-2.3,0,0,GO:0046847,filopodium assembly,M100,1,0
